Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2016 | Feb. 21, 2017 | Jun. 30, 2016 | |
Document and Entity Information [Abstract] | |||
Entity Registrant Name | BALCHEM CORP | ||
Entity Central Index Key | 9,326 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Public Float | $ 1,867,000,000 | ||
Entity Common Stock, Shares Outstanding | 31,770,824 | ||
Document Fiscal Year Focus | 2,016 | ||
Document Fiscal Period Focus | FY | ||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2016 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
Current assets: | ||
Cash and cash equivalents | $ 38,643 | $ 84,795 |
Accounts receivable, net of allowance for doubtful accounts of $489 and $235 at December 31, 2016 and 2015, respectively | 83,252 | 60,485 |
Inventories | 57,245 | 46,085 |
Prepaid expenses | 4,110 | 3,208 |
Deferred income taxes | 712 | 810 |
Other current assets | 4,480 | 2,909 |
Total current assets | 188,442 | 198,292 |
Property, plant and equipment, net | 165,754 | 158,515 |
Goodwill | 439,811 | 383,906 |
Intangible assets with finite lives, net | 147,484 | 134,911 |
Other assets | 7,135 | 4,062 |
Total assets | 948,626 | 879,686 |
Current liabilities: | ||
Trade accounts payable | 32,514 | 14,708 |
Accrued expenses | 14,758 | 12,829 |
Accrued compensation and other benefits | 6,648 | 5,128 |
Dividends payable | 12,088 | 10,727 |
Income taxes payable | 0 | 2,728 |
Current portion of long-term debt | 35,000 | 35,000 |
Total current liabilities | 101,008 | 81,120 |
Long-term debt | 226,490 | 260,963 |
Revolving loan - long-term | 19,000 | 0 |
Deferred income taxes | 74,199 | 67,215 |
Other long-term obligations | 6,896 | 6,683 |
Total liabilities | 427,593 | 415,981 |
Commitments and contingencies (note 12) | ||
Stockholders' equity: | ||
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding | 0 | 0 |
Common stock, $.0667 par value. Authorized 120,000,000 shares; 31,757,861 shares issued and outstanding at December 31, 2016 and 31,528,449 shares issued and 31,527,360 outstanding at December 31, 2015 | 2,117 | 2,102 |
Additional paid-in capital | 137,676 | 122,594 |
Retained earnings | 388,089 | 344,197 |
Accumulated other comprehensive loss | (6,849) | (5,114) |
Treasury stock, at cost: 0 and 1,089 shares at December 31, 2016 and 2015, respectively | 0 | (74) |
Total stockholders' equity | 521,033 | 463,705 |
Total liabilities and stockholders' equity | $ 948,626 | $ 879,686 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
Current assets: | ||
Allowance for doubtful accounts | $ 489 | $ 235 |
Stockholders' equity: | ||
Preferred stock, par value (in dollars per share) | $ 25 | $ 25 |
Preferred stock, shares authorized (in shares) | 2,000,000 | 2,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.0667 | $ 0.0667 |
Common stock, shares authorized (in shares) | 120,000,000 | 120,000,000 |
Common stock, shares issued (in shares) | 31,757,861 | 31,528,449 |
Common stock, shares outstanding (in shares) | 31,757,861 | 31,527,360 |
Treasury stock (in shares) | 0 | 1,089 |
Consolidated Statements of Earn
Consolidated Statements of Earnings - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Consolidated Statements of Earnings [Abstract] | |||
Net sales | $ 553,204 | $ 552,492 | $ 541,383 |
Cost of sales | 372,343 | 384,395 | 397,211 |
Gross margin | 180,861 | 168,097 | 144,172 |
Operating expenses: | |||
Selling expenses | 55,172 | 46,255 | 35,758 |
Research and development expenses | 7,325 | 5,990 | 4,810 |
General and administrative expenses | 27,526 | 21,896 | 21,461 |
Total operating expenses | 90,023 | 74,141 | 62,029 |
Earnings from operations | 90,838 | 93,956 | 82,143 |
Other expenses (income): | |||
Interest income | (9) | (9) | (64) |
Interest expense | 7,265 | 6,593 | 5,145 |
Other, net | 648 | 309 | 10 |
Earnings before income tax expense | 82,934 | 87,063 | 77,052 |
Income tax expense | 26,962 | 27,341 | 24,226 |
Net earnings | $ 55,972 | $ 59,722 | $ 52,826 |
Basic net earnings per common share (in dollars per share) | $ 1.78 | $ 1.92 | $ 1.74 |
Diluted net earnings per common share (in dollars per share) | $ 1.75 | $ 1.89 | $ 1.69 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Consolidated Statements of Comprehensive Income [Abstract] | |||
Net earnings | $ 55,972 | $ 59,722 | $ 52,826 |
Other comprehensive loss, net of tax: | |||
Net foreign currency translation adjustment | (1,390) | (2,615) | (2,972) |
Net change in postretirement benefit plan, net of taxes of $49, $72, and $56 at December 31, 2016, 2015, and 2014, respectively | (345) | 152 | 123 |
Other comprehensive loss | (1,735) | (2,463) | (2,849) |
Comprehensive income | $ 54,237 | $ 57,259 | $ 49,977 |
Consolidated Statements of Com6
Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Other comprehensive loss, net of tax: | |||
Net change in postretirement benefit plan, taxes | $ 49 | $ 72 | $ 56 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands | Total | Retained Earnings [Member] | Accumulated Other Comprehensive Income (Loss) [Member] | Common Stock [Member] | Treasury Stock [Member] | Additional Paid-in Capital [Member] |
Balance at Dec. 31, 2013 | $ 331,358 | $ 251,627 | $ 198 | $ 2,016 | $ 0 | $ 77,517 |
Balance (in shares) at Dec. 31, 2013 | 30,225,763 | 0 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net earnings | 52,826 | 52,826 | 0 | $ 0 | $ 0 | 0 |
Other comprehensive loss | (2,849) | 0 | (2,849) | 0 | 0 | 0 |
Dividends | (9,251) | (9,251) | 0 | 0 | 0 | 0 |
Treasury shares purchased | (1,068) | 0 | 0 | $ 0 | $ (1,068) | 0 |
Treasury shares purchased (in shares) | 0 | (17,497) | ||||
Shares and options issued under stock plans and an income tax benefit | 20,882 | 0 | 0 | $ 42 | $ 1,068 | 19,772 |
Shares and options issued under stock plans and an income tax benefit (in shares) | 619,823 | 17,497 | ||||
Balance at Dec. 31, 2014 | 391,898 | 295,202 | (2,651) | $ 2,058 | $ 0 | 97,289 |
Balance (in shares) at Dec. 31, 2014 | 30,845,586 | 0 | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net earnings | 59,722 | 59,722 | 0 | $ 0 | $ 0 | 0 |
Other comprehensive loss | (2,463) | 0 | (2,463) | 0 | 0 | 0 |
Dividends | (10,727) | (10,727) | 0 | 0 | 0 | 0 |
Treasury shares purchased | (1,205) | 0 | 0 | $ 0 | $ (1,205) | 0 |
Treasury shares purchased (in shares) | 0 | (20,692) | ||||
Shares and options issued under stock plans and an income tax benefit | 26,480 | 0 | 0 | $ 44 | $ 1,131 | 25,305 |
Shares and options issued under stock plans and an income tax benefit (in shares) | 682,863 | 19,603 | ||||
Balance at Dec. 31, 2015 | 463,705 | 344,197 | (5,114) | $ 2,102 | $ (74) | 122,594 |
Balance (in shares) at Dec. 31, 2015 | 31,528,449 | (1,089) | ||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net earnings | 55,972 | 55,972 | 0 | $ 0 | $ 0 | 0 |
Other comprehensive loss | (1,735) | 0 | (1,735) | 0 | 0 | 0 |
Dividends | (12,080) | (12,080) | 0 | 0 | 0 | 0 |
Treasury shares purchased | (1,588) | 0 | 0 | $ 0 | $ (1,588) | 0 |
Treasury shares purchased (in shares) | 0 | (24,912) | ||||
Shares and options issued under stock plans and an income tax benefit | 16,759 | 0 | 0 | $ 15 | $ 1,662 | 15,082 |
Shares and options issued under stock plans and an income tax benefit (in shares) | 229,412 | 26,001 | ||||
Balance at Dec. 31, 2016 | $ 521,033 | $ 388,089 | $ (6,849) | $ 2,117 | $ 0 | $ 137,676 |
Balance (in shares) at Dec. 31, 2016 | 31,757,861 | 0 |
Consolidated Statements of Sto8
Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Consolidated Statements of Stockholders' Equity [Abstract] | |||
Dividends (in dollars per share) | $ 0.38 | $ 0.34 | $ 0.30 |
Income tax benefit of shares and options issued under stock plans | $ 2,546 | $ 7,009 | $ 7,220 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Cash flows from operating activities: | |||
Net earnings | $ 55,972 | $ 59,722 | $ 52,826 |
Adjustments to reconcile net earnings to net cash provided by operating activities: | |||
Depreciation and amortization | 46,202 | 39,964 | 30,524 |
Stock compensation expense | 7,024 | 6,829 | 4,557 |
Deferred income taxes | (6,881) | (2,857) | (11,259) |
Provision for doubtful accounts | 258 | (53) | 238 |
Foreign currency transaction loss | (16) | 25 | 105 |
Loss on disposal of assets | 320 | 301 | 150 |
Changes in assets and liabilities, net of acquired balances | |||
Accounts receivable | (15,659) | 10,809 | (8,395) |
Inventories | 4,745 | 3,126 | 6,698 |
Prepaid expenses and other current assets | 240 | 1,233 | (848) |
Accounts payable and accrued expenses | 17,841 | (15,718) | 7,747 |
Income taxes | (2,765) | 633 | 3,370 |
Other | 331 | (188) | (363) |
Net cash provided by operating activities | 107,612 | 103,826 | 85,350 |
Cash flows from investing activities: | |||
Capital expenditures | (23,034) | (41,300) | (13,199) |
Cash paid for acquisition, net of cash acquired | (110,601) | 0 | (491,057) |
Proceeds from sale of property, plant and equipment | 4 | 34 | 1 |
Proceeds from insurance | 1,000 | 0 | 0 |
Intangible assets acquired | (963) | (1,011) | (169) |
Net cash used in investing activities | (133,594) | (42,277) | (504,424) |
Cash flows from financing activities: | |||
Proceeds from long-term debt | 0 | 0 | 350,000 |
Principal payments on long-term debt | (35,000) | (35,000) | (17,500) |
Proceeds from revolving loan | 72,500 | 0 | 50,000 |
Principal payments on revolving loan | (53,500) | 0 | (50,000) |
Principal payment on acquired debt | (884) | 0 | (75,550) |
Cash paid for financing costs | 0 | 0 | (2,593) |
Repayments of short-term obligations | 0 | 0 | (89) |
Proceeds from stock options exercised | 7,192 | 12,605 | 9,106 |
Excess tax benefits from stock compensation | 2,546 | 7,009 | 7,220 |
Dividends paid | (10,720) | (9,251) | (7,856) |
Purchase of treasury stock | (1,588) | (1,205) | (1,068) |
Net cash (used in)/provided by financing activities | (19,454) | (25,842) | 261,670 |
Effect of exchange rate changes on cash | (716) | (1,199) | (1,056) |
(Decrease)/Increase in cash and cash equivalents | (46,152) | 34,508 | (158,460) |
Cash and cash equivalents beginning of period | 84,795 | 50,287 | 208,747 |
Cash and cash equivalents end of period | $ 38,643 | $ 84,795 | $ 50,287 |
BUSINESS DESCRIPTION AND SUMMAR
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2016 | |
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] | |
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 1 - BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Description Balchem Corporation (including, unless the context otherwise requires, its wholly-owned subsidiaries, SensoryEffects, Inc., SensoryEffects Cereal Systems, Inc., Albion International, Inc., BCP Ingredients, Inc., Aberco, Inc., Balchem BV, Balchem Italia Srl, and Balchem LTD (“Balchem” or the “Company”)), incorporated in the State of Maryland in 1967, is engaged in the development, manufacture and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, agricultural, and medical sterilization industries. Principles of Consolidation The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Revenue Recognition Revenue for each of our business segments is recognized upon product shipment, passage of title and risk of loss, and when collection is reasonably assured. The Company reports amounts billed to customers related to shipping and handling as revenue and includes costs incurred for shipping and handling in cost of sales. Amounts received for unshipped merchandise are not recognized as revenue but rather they are recorded as customer deposits and are included in current liabilities. In instances of shipments made on consignment, revenue is deferred until a customer indicates to the Company that it has used the Company’s products. The Company does not charge its customers rental fees on cylinders or drums used to ship its products. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents. The Company has Accounts Receivable Credit terms are granted in the normal course of business to our customers. On-going credit evaluations are performed on our customers and credit limits are adjusted based upon payment history and the customer's current credit worthiness, as determined through review of their current credit information. Collections and payments from customers are continuously monitored and allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments are maintained. Estimated losses are based on historical experience and any specific customer collection issues identified. Inventories Inventories are valued at the lower of cost (first in, first out or average) or market value and have been reduced by an allowance for excess or obsolete inventories. Cost elements include material, labor and manufacturing overhead. Property, Plant and Equipment and Depreciation Property, plant and equipment are stated at cost. Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows: Buildings 15-25 Equipment 2-28 years Expenditures for repairs and maintenance are charged to expense. Alterations and major overhauls that extend the lives or increase the capacity of plant assets are capitalized. When assets are retired or otherwise disposed of, the cost of the assets and the related accumulated depreciation are removed from the accounts and any resultant gain or loss is included in earnings. Business Concentrations Financial instruments that subject the Company to credit risk consist primarily of accounts receivable and money market investments. Investments are managed within established guidelines to mitigate risks. Accounts receivable subject the Company to credit risk partially due to the concentration of amounts due from customers. The Company extends credit to its customers based upon an evaluation of the customers’ financial condition and credit histories. The majority of the Company’s customers are major national or international corporations. In 2016, 2015 and 2014, no customer accounted for more than 10% of total net sales. Goodwill and Acquired Intangible Assets Goodwill represents the excess of costs over fair value of assets of businesses acquired. ASC 350, “Intangibles-Goodwill and Other,” requires the use of the acquisition method of accounting for a business combination and defines an intangible asset. Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized, but are instead assessed for impairment annually and more frequently if events and circumstances indicate that the asset might be impaired, in accordance with the provisions of ASC 350. The Company performs its annual test as of October 1. ASC 350 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment if events and circumstances indicate that the asset might be impaired. In accordance with ASU No. 2011-08, “Intangibles—Goodwill and Other (Topic 350): Testing Goodwill for Impairment” (“ASU 2011-08”) As of October 1, 2016 and 2015, the Company opted to bypass the qualitative assessment and proceeded directly to performing the first step of the goodwill impairment test. We assessed the fair values of our reporting units by utilizing the income approach, based on a discounted cash flow valuation model as the basis for our conclusions, as well as market approaches for certain reporting units. Our estimates of future cash flows included significant management assumptions such as revenue growth rates, operating margins, discount rates, estimated terminal values and future economic and market conditions. Our assessment concluded that the fair values of the reporting units exceeded their carrying amounts, including goodwill. Accordingly, the goodwill of the reporting units is not considered impaired. The Company may resume performing the qualitative assessment in subsequent periods. The Company had goodwill in the amount of $439,811 and $383,906 as of December 31, 2016 and December 31, 2015, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” Goodwill at January 1, 2016 $ 383,906 Goodwill as a result of the Acquisition of Albion International, Inc. – see Note 2 55,905 Goodwill at December 31, 2016 $ 439,811 There was a $4,272 reduction in the carrying amount of goodwill during the three months ended December 31, 2016, as a result of changes to the fair value of assets acquired December 31, 2016 December 31, 2015 Human Nutrition & Health $ 404,187 $ 363,784 Animal Nutrition & Health 11,734 11,734 Specialty Products 22,662 7,160 Industrial Products 1,228 1,228 Total $ 439,811 $ 383,906 The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives: Amortization Period Customer relationships and lists 10 Trademarks & trade names 17 Developed technology 5 Regulatory registration costs 5 - 10 Patents & trade secrets 15 - 17 Other 5 - 10 For the year ended December 31, 2016, there were no triggering events which required intangible asset impairment reviews. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Use of Estimates Management of the Company is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and revenues and expenses during the reporting period. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Actual results could differ from those estimates. Fair Value of Financial Instruments The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at December 31, 2016 and 2015 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable and accrued liabilities, and are carried at cost which approximates fair value due to the short-term maturity of these instruments. Cost of Sales Cost of sales are primarily comprised of raw materials and supplies consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and direct overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense. Selling, General and Administrative Expenses Selling expenses consist primarily of compensation and benefit costs, amortization of customer relationships and lists, trade promotions, advertising, commissions and other marketing costs. General and administrative expenses consist primarily of payroll and benefit costs, occupancy and operating costs of corporate offices, depreciation and amortization expense on non-manufacturing assets, information systems costs and other miscellaneous administrative costs. Research and Development Research and development costs are expensed as incurred. Net Earnings Per Common Share Basic net earnings per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share is calculated in a manner consistent with basic net earnings per common share except that the weighted average number of common shares outstanding also includes the dilutive effect of stock options outstanding, unvested restricted stock, and unvested performance shares (using the treasury stock method). Stock-based Compensation The Company has stock-based employee compensation plans, which are described more fully in Note 3. The Company accounts for stock-based compensation in accordance with ASC 718, “Compensation-Stock Compensation,” which requires all share-based payments, including grants of stock options, to be recognized in the income statement as an operating expense, based on their fair values. The Company estimates the fair value of each option award on the date of grant using a Black-Scholes based option-pricing model. Estimates of and assumptions about forfeiture rates, terms, volatility, interest rates and dividend yields are used to calculate stock-based compensation. A significant change to these estimates could materially affect the Company’s operating results. Impairment of Long-lived Assets Long-lived assets, such as property, plant, and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), with amendments issued in 2016, which addresses revenue recognition issues and, upon its effective date, replaces almost all existing revenue recognition guidance, including industry-specific guidance, in current U.S. GAAP. This standard is effective, with either a full retrospective approach or a modified retrospective approach, for annual and interim periods beginning after December 15, 2017. We are assessing the impact of the guidance on our current accounting practices to identify differences that would result from applying the new requirements to our revenue contracts. We continue to make significant progress on our contract reviews and are also still in the process of evaluating the impact, if any, on changes to our business processes, systems, and controls to support recognition and disclosure under the new guidance. Based on our findings so far, we do not currently expect this guidance to have a material impact on our financial statements. We are continuing our implementation plan and currently expect to adopt the new guidance beginning in 2018 using the modified retrospective approach. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory” (“ASU 2015-11”), which requires inventory to be measured at the lower of cost and net realizable value. This standard is effective prospectively for annual and interim periods beginning after December 15, 2016. Although, early adoption is permitted, the Company has elected not to adopt early as this ASU will not have a significant impact on the Company’s consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), to simplify the presentation of deferred income taxes. The ASU requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This standard is effective prospectively for annual and interim periods beginning after December 15, 2016. Although, early adoption is permitted, the Company has elected not to adopt early as this ASU will not have a significant impact on the Company’s consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases” (“ASU 2016-02”), which addresses the recognition of assets and liabilities that arise from all leases. The guidance requires lessees to recognize right-to-use assets and lease liabilities for most leases in the Consolidated Balance Sheets. The guidance is effective for annual and interim periods beginning after December 15, 2018 and early adoption is permitted. The Company is currently evaluating the impact of the new guidance. In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”), which addresses the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for annual and interim periods beginning after December 15, 2016. Although, early adoption is permitted, the Company has elected not to adopt early. We expect that the adoption of this new guidance in 2017 will reduce our reported income taxes and will increase cash flows from operating activities; however, the amounts of that reduction/increase is dependent upon the underlying vesting or exercise activity and related future stock prices. In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business” (“ASU 2017-01”), which addresses the definition of what constitutes a business by providing clarification of the three elements that constitutes a business. The guidance is effective for annual and interim periods beginning after December 15, 2017. Although, early adoption is permitted, the Company has elected not to adopt early as this ASU will not have a significant impact on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Although, early adoption is permitted, the Company has elected not to adopt early as this ASU will not have a significant impact on the Company’s consolidated financial statements. Reclassifications Certain reclassifications have been made to the prior years’ financial statements to conform to the current year’s presentation with no impact on net earnings or stockholders’ equity. |
ACQUISITIONS
ACQUISITIONS | 12 Months Ended |
Dec. 31, 2016 | |
ACQUISITIONS [Abstract] | |
ACQUISITIONS | NOTE 2 – ACQUISITIONS Acquisition of Albion International, Inc. On February 1, 2016, the Company acquired 100 percent of the outstanding common shares of Albion International, Inc. (“Albion” or the “Acquisition”), a privately held manufacturer of mineral amino acid chelates, specialized mineral salts and mineral complexes, headquartered in Clearfield, Utah. The Company made payments of approximately $116.4 million on the acquisition date, amounting to approximately $110.6 million to the former shareholders, adjustments for working capital acquired of $4.9 million, and approximately $0.9 million to Albion’s lenders to pay off all Albion bank debt. Albion has been a world leader and innovator in the manufacture of superior organic mineral compounds for sixty years and leverages scientific expertise in the areas of human and micronutrient agricultural nutrition. Albion’s products are renowned in the supplement industry for technologically advanced, unparalleled bioavailability. The acquisition of Albion continues to expand the Company’s science based human health and wellness solutions and will immediately increase our product offerings in the nutritional ingredient market. Additionally, the Company will also benefit from a broader geographic footprint and a stronger position as a technological leader in spray-drying and ingredient delivery solutions. Albion’s human nutrition business has become a part of the Human Nutrition & Health reportable segment and the micronutrient agricultural business has become a part of the Specialty Products reportable segment. The following table summarizes the fair values of the assets acquired and liabilities assumed. Cash and cash equivalents $ $ 4,949 Accounts receivable 7,671 Inventories 15,989 Property, plant and equipment 7,217 Customer relationships 18,443 Developed technology 9,060 Trade name 7,224 Licensing agreements 6,658 Other assets 1,200 Trade accounts payable (1,104 ) Accrued expenses (2,788 ) Bank debt (884 ) Deferred income taxes (13,990 ) Goodwill 55,905 Amount paid to shareholders 115,550 Albion bank debt paid on purchase date 884 Total amount paid on acquisition date $ $ 116,434 The goodwill of $55,905 arising from the Acquisition consists largely of expected synergies, including the combined entities’ experience and technical problem solving capabilities, and acquired workforce. Goodwill of $40,403 and $15,502 is assigned to the Human Nutrition & Health and Specialty Products segments, respectively, and approximately $2,020 is tax deductible for income tax purposes. The valuation of the fair value of tangible and intangible assets acquired and liabilities assumed are based on management’s estimates and assumptions. In preparing our fair value of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Customer relationships are amortized over a 10-year period utilizing an accelerated method based on the estimated average customer attrition rate. Trade name, licensing agreements, and developed technology are amortized over 17 years, 8 years, and 5 years, respectively, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined. Transaction and integration related costs included in selling, and general and administrative expenses for the year ended December 31, 2016 are $1,499. The following unaudited pro forma information has been prepared as if the Acquisition had occurred on January 1, 2015. Year Ended December 31, 2016 Year Ended December 31, 2015 Net Sales Net Earnings Net Sales Net Earnings Albion’s actual results included in the Company’s consolidated income statement $ $49,608 $ $ 2,938 $ - $ - Supplemental pro forma combined financial information $ $557,784 $ $ 60,840 $ $ 605,273 $ $ 56,109 Basic earnings per share $ $ 1.93 $ $ 1.80 Diluted earnings per share $ $ 1.91 $ $ 1.77 2016 supplemental pro forma earnings for the year ended December 31, 2016 exclude $26,210 of acquisition-related costs incurred and $5,363 of nonrecurring expenses related to the fair value adjustment to acquisition-date inventory. The pro forma information presented does not purport to be indicative of the results that actually would have been attained if the Albion acquisition had occurred at the beginning of the periods presented and is not intended to be a projection of future results. |
STOCKHOLDERS' EQUITY
STOCKHOLDERS' EQUITY | 12 Months Ended |
Dec. 31, 2016 | |
STOCKHOLDERS' EQUITY [Abstract] | |
STOCKHOLDERS' EQUITY | NOTE 3 - STOCKHOLDERS’ EQUITY STOCK-BASED COMPENSATION All share-based payments, including grants of stock options, are recognized in the income statement as an operating expense, based on their fair values. The Company has made an estimate of expected forfeitures, based on its historical experience, and is recognizing compensation cost only for those stock-based compensation awards expected to vest. Additionally, excess tax benefits related to stock compensation are presented as a cash inflow from financing activities. The change had the effect of decreasing cash flows from operating activities and increasing cash flows from financing activities by $2,546, $7,009, and $7,220 for the years ended December 31, 2016, 2015 and 2014, respectively. The Company’s results for the years ended December 31, 2016, 2015 and 2014 reflected the following compensation cost and such compensation cost had the following effects on net earnings: Increase/(Decrease) for the Years Ended December 31, 2016 2015 2014 Cost of sales $ 1,040 $ 854 $ 593 Operating expenses 5,984 5,975 3,964 Net earnings (4,473 ) (4,395 ) (2,926 ) On December 31, 2016, the Company had one share-based compensation plan, which is described below (the “1999 Stock Plan”). In June 1999, the Company adopted the Balchem Corporation 1999 Stock Plan for officers, directors, directors emeritus and employees of and consultants to the Company and its subsidiaries. The 1999 Stock Plan is administered by the Compensation Committee of the Board of Directors of the Company. Under the plan, options and rights to purchase shares of the Company’s Common Stock are granted at prices established at the time of grant. Option grants generally become exercisable 20% after 1 year, 60% after 2 years and 100% after 3 years from the date of grant for employees and are fully exercisable on the date of grant for directors. Other option grants are either fully exercisable on the date of grant or become exercisable thereafter in such installments as the Committee may specify. Options granted under the 1999 Stock Plan expire ten years from the date of grant. The 1999 Stock Plan initially reserved an aggregate of 600,000 shares (unadjusted for the stock splits) of Common Stock for issuance under the Plan. In April 2003, the Board of Directors of the Company adopted and stockholders subsequently approved, the Amended and Restated 1999 Stock Plan (the “Amended Plan”) which amended the 1999 Stock Plan by: (i) increasing the number of shares of Common Stock reserved for issuance under the 1999 Stock Plan by 600,000 shares (unadjusted for the stock splits), to a total of 1,200,000 shares (unadjusted for the stock splits) of Common Stock; and (ii) confirming the right of the Company to grant awards of Common Stock (“Awards”) in addition to the other Stock Rights available under the 1999 Stock Plan, and providing certain language changes relating thereto. The Amended Plan was scheduled to expire in April 2009. In April 2008, the Board of Directors of the Company adopted and stockholders subsequently approved, the adoption of an amendment and restatement of the Amended Plan (collectively to be referred to as the “Second Amended Plan”), which provides as follows: (i) for a termination date of April 9, 2018; (ii) to authorize 6,000,000 shares reserved for future grants under the Second Amended Plan; (iii) for the making of grants of stock appreciation rights, restricted stock and performance awards; (iv) for immediate acceleration of vesting of awards issued under the plan in the event of a change in control of the Company; and (v) for compliance with the requirements of Sections 409A and 162(m) of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code” or the “Code”). The shares to be issued upon exercise of the outstanding options have been approved, reserved and are adequate to cover all exercises. As of December 31, 2016, the plans had 3,476,571 shares available for future awards. The Company has Restricted Stock Purchase Agreements (the “RSP Agreements”) with its non-employee directors and certain employees of the Company to purchase the Company’s Common Stock pursuant to the Company’s 1999 Stock Plan. Under the RSP Agreements, certain shares have been purchased, ranging from 1,000 shares to 20,250 shares, of the Company’s Common Stock at purchase prices ranging from approximately $.02 per share to $.07 per share. The purchased stock is subject to a repurchase option in favor of the Company and to restrictions on transfer until it vests in accordance with the provisions of the RSP Agreements. In 2011, the Company discontinued the use of RSP Agreements and replaced them with Restricted Stock Grant Agreements for the Company’s non-employee directors and certain employees. Under the Restricted Stock Grant Agreements, certain shares of the Company’s Common Stock have been granted, ranging from 500 shares to 54,000 shares, to its non-employee directors and certain employees, subject to time-based vesting requirements. The Company also has performance share (“PS”) awards, which provide the recipients the right to receive a certain number of shares of the Company’s common stock in the future, subject to an (1) EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period, and (2) relative total shareholder return (“TSR”) where vesting is dependent upon the Company’s TSR performance over the performance period relative to a comparator group consisting of the Russell 2000 index constituents. The fair value of each option award issued under the 1999 Stock Plan is estimated on the date of grant using a Black-Scholes based option-pricing model that uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of the Company’s stock. The expected term of the options is based on the Company’s historical experience of employees’ exercise behavior. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life. Weighted Average Assumptions: 2016 Years Ended 2015 2014 Expected Volatility 34.4 % 33.2 % 33.7 % Expected Term (in years) 5.0 5.5 5.6 Risk-Free Interest Rate 1.2 % 1.7 % 1.8 % Dividend Yield 0.5 % 0.6 % 0.5 % The value of the restricted shares is based on the fair value of the award at the date of grant. PS expense is measured based on the fair value at the date of grant utilizing a Black-Scholes methodology to produce a Monte-Carlo simulation model which allows for the incorporation of the performance hurdles that must be met before the PS vests. The assumptions used in the fair value determination were risk free interest rates of 0.88% and 1.00%; dividend yields of 0.6% and 0.5%; volatilities of 32% and 34%; and initial TSR’s of -6.6% and -6.9%, in each case for the years ended December 31, 2016 and 2015, respectively. Expense is based on the estimated number of shares expected to vest, assuming the requisite service period is rendered and the probable outcome of the performance condition is achieved. The estimate is revised if subsequent information indicates that the actual number of shares likely to vest differs from previous estimates. Expense is ultimately adjusted based on the actual achievement of service and performance targets. The PS will cliff vest 100% at the end of the third year following the grant in accordance with the performance metrics set forth. Compensation expense for stock options and stock awards is recognized on a straight-line basis over the vesting period, generally three years for stock options, four years for employee restricted stock awards, three years for employee performance share awards, and four years for non-employee director restricted stock awards. A summary of stock option plan activity for 2016, 2015, and 2014 for all plans is as follows: 2016 # of Shares (000s) Weighted Average Exercise Price Outstanding at beginning of year 1,017 $ 37.29 Granted 341 60.92 Exercised (236 ) 30.44 Forfeited (56 ) 58.23 Outstanding at end of year 1,066 $ 45.32 Exercisable at end of year 604 $ 34.77 2015 # of Shares (000s) Weighted Average Exercise Price Outstanding at beginning of year 1,470 $ 27.35 Granted 209 58.34 Exercised (627 ) 20.16 Forfeited (35 ) 52.97 Outstanding at end of year 1,017 $ 37.29 Exercisable at end of year 667 $ 29.19 2014 # of Shares (000s) Weighted Average Exercise Price Outstanding at beginning of year 1,893 $ 20.94 Granted 313 53.38 Exercised (610 ) 14.92 Forfeited (126 ) 56.03 Outstanding at end of year 1,470 $ 27.35 Exercisable at end of year 1,066 $ 21.52 The aggregate intrinsic value for outstanding stock options was $41,161, $23,927 and $57,742 at December 31, 2016, 2015 and 2014, respectively, with a weighted average remaining contractual term of 6.2 years at December 31, 2016. Exercisable stock options at December 31, 2016 had an aggregate intrinsic value of $29,680 with a weighted average remaining contractual term of 4.6 years. Other information pertaining to option activity during the years ended December 31, 2016, 2015 and 2014 was as follows: Years Ended December 31, 2016 2015 2014 Weighted-average fair value of options granted $ 18.48 $ 18.35 $ 17.36 Total intrinsic value of stock options exercised ($000s) $ 8,609 $ 24,047 $ 25,224 Additional information related to stock options outstanding under all plans at December 31, 2016 is as follows: Options Outstanding Options Exercisable Range of Exercise Prices Shares Outstanding (000s) Weighted Average Remaining Contractual Term Weighted Average Exercise Price Number Exercisable (000s) Weighted Average Exercise Price $ 13.61 - $34.81 356 3.5 years $ 25.40 356 $ 25.40 38.10 - 59.95 406 6.6 years 51.03 224 46.89 60.01 - 80.26 304 9.0 years 61.00 24 60.84 1,066 6.2 years $ 45.32 604 $ 34.77 Non-vested restricted stock activity for the years ended December 31, 2016, 2015 and 2014 is summarized below: Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2015 150 $ 47.46 Granted 19 61.22 Vested (66 ) 40.96 Forfeited (1 ) 56.77 Non-vested balance as of December 31, 2016 102 $ 54.18 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2014 134 $ 38.13 Granted 77 55.77 Vested (61 ) 37.35 Forfeited - - Non-vested balance as of December 31, 2015 150 $ 47.46 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2013 172 $ 33.69 Granted 33 54.86 Vested (65 ) 34.19 Forfeited (6 ) 45.32 Non-vested balance as of December 31, 2014 134 $ 38.13 Non-vested performance share activity for the years ended December 31, 2016, 2015 and 2014 is summarized below: Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2015 20 $ 58.77 Granted 22 63.15 Vested - - Forfeited (8 ) 60.88 Non-vested balance as of December 31, 2016 34 $ 61.06 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2014 - $ - Granted 29 58.77 Vested - - Forfeited (9 ) 58.77 Non-vested balance as of December 31, 2015 20 $ 58.77 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2013 - $ - Granted - - Vested - - Forfeited - - Non-vested balance as of December 31, 2014 - $ - As of December 31, 2016, 2015 and 2014, there was $8,260, $7,705 and $5,981, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. As of December 31, 2016, the unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 1.4 years. We estimate that share-based compensation expense for the year ended December 31, 2017 will be approximately $6,900. REPURCHASE OF COMMON STOCK The Company has an approved stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 2,150,835 shares have been purchased, of which -0- and 1,089 remained in treasury at December 31, 2016 and 2015, respectively. During 2016, a total of 24,912 shares have been purchased at an average cost of $63.76 per share. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it advisable to do so based on its assessment of corporate cash flow, market conditions and other factors. |
INVENTORIES
INVENTORIES | 12 Months Ended |
Dec. 31, 2016 | |
INVENTORIES [Abstract] | |
INVENTORIES | NOTE 4 - INVENTORIES Inventories at December 31, 2016 and 2015 consisted of the following: 2016 2015 Raw materials $ 20,751 $ 16,786 Work in progress 3,225 1,807 Finished goods 33,269 27,492 Total inventories $ 57,245 $ 46,085 On a regular |
PROPERTY, PLANT AND EQUIPMENT
PROPERTY, PLANT AND EQUIPMENT | 12 Months Ended |
Dec. 31, 2016 | |
PROPERTY, PLANT AND EQUIPMENT [Abstract] | |
PROPERTY, PLANT AND EQUIPMENT | NOTE 5 - PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment at December 31, 2016 and 2015 are summarized as follows: 2016 2015 Land $ 4,208 $ 3,247 Building 45,735 33,051 Equipment 177,841 153,682 Construction in progress 17,357 39,525 245,141 229,505 Less: Accumulated depreciation 79,387 70,990 Property, plant and equipment, net $ 165,754 $ 158,515 Depreciation expense was $15,907, $12,895 and $10,599 for the years ended December 31, 2016, 2015 and 2014, respectively. |
INTANGIBLE ASSETS
INTANGIBLE ASSETS | 12 Months Ended |
Dec. 31, 2016 | |
INTANGIBLE ASSETS [Abstract] | |
INTANGIBLE ASSETS | NOTE 6 - INTANGIBLE ASSETS The Company had goodwill in the amount of $439,811 and $383,906 as of December 31, 2016 and 2015 subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” As of December 31, 2016 and 2015, the Company had identifiable intangible assets as follows: Amortization Period (In years) 2016 Gross Carrying Amount 2016 Accumulated Amortization 2015 Gross Carrying Amount 2015 Accumulated Amortization Customer relationships & lists 10 $ 185,885 $ 86,338 $ 167,442 $ 63,578 Trademarks & trade names 17 39,241 9,260 32,014 5,704 Developed technology 5 12,260 3,358 3,200 1,057 Other 5-17 12,713 3,659 5,102 2,508 $ 250,099 $ 102,615 $ 207,758 $ 72,847 Amortization of identifiable intangible assets was $29,768, $26,467 and $19,468 for 2016, 2015 and 2014, respectively. Assuming no change in the gross carrying value of identifiable intangible assets, the estimated amortization expense is approximately $26,160 in 2017, $23,641 in 2018, $21,604 in 2019, $19,634 in 2020 and $16,472 in 2021. At December 31, 2016 and 2015, there were no identifiable intangible assets with indefinite useful lives as defined by ASC 350, “Intangibles-Goodwill and Other.” Identifiable intangible assets are reflected in the Company’s consolidated balance sheets under Intangible assets with finite lives, net. There were no changes to the useful lives of intangible assets subject to amortization in 2016 and 2015. The Federal Insecticide, Fungicide and Rodenticide Act, (“FIFRA”), a health and safety statute, requires that certain products within our specialty products segment must be registered with the U.S. Environmental Protection Agency (“EPA”) because they are considered pesticides. Costs of such registration are included as other in the table above. |
EQUITY-METHOD INVESTMENT
EQUITY-METHOD INVESTMENT | 12 Months Ended |
Dec. 31, 2016 | |
EQUITY-METHOD INVESTMENT [Abstract] | |
EQUITY-METHOD INVESTMENT | NOTE 7 – EQUITY-METHOD INVESTMENT In 2013, the Company and Eastman Chemical Company (formerly Taminco Corporation) formed a joint venture (66.66% / 33.34% ownership), St. Gabriel CC Company, LLC, to design, develop, and construct an expansion of the Company’s St. Gabriel aqueous choline chloride plant. The Company contributed the St. Gabriel plant, at cost, and expansion will be funded by the owners. The joint venture became operational as of July 1, 2016. St. Gabriel CC Company, LLC is a Variable Interest Entity (VIE) because the total equity at risk is not sufficient to permit the joint venture to finance its own activities without additional subordinated financial support. Additionally, voting rights (2 votes each) are not proportionate to the owners’ obligation to absorb expected losses or receive the expected residual returns of the joint venture. The Company will receive up to 2/3 of the production offtake capacity and absorbs operating expenses approximately proportional to the actual percentage of offtake. The joint venture is accounted for under the equity method of accounting since the Company is not the primary beneficiary as we do not have the power to direct the activities of the joint venture that most significantly impact its economic performance. The Company recognized a loss of $293 relating to its portion of the joint venture’s expenses in other expense. The carrying value of the joint venture at December 31, 2016 is $4,553 and is recorded in other assets. |
LONG TERM DEBT
LONG TERM DEBT | 12 Months Ended |
Dec. 31, 2016 | |
LONG TERM DEBT [Abstract] | |
LONG TERM DEBT | NOTE 8 – LONG TERM DEBT On May 7, 2014, the Company and a bank syndicate entered into a loan agreement providing for a senior secured term loan of $350,000 and revolving loan of $100,000 (collectively referred to as the “loans”). On February 1, 2016, $65,000 of the revolving loan was used to fund the Albion International, Inc. acquisition (see Note 2). At December 31, 2016, the Company had a total of $281,500 of debt outstanding. The term loan is payable in quarterly installments of $8,750 commencing on September 30, 2014, with the outstanding principal due on the maturity date. The Company may draw on the revolving loan at its discretion. The revolving loan does not have installments and all outstanding amounts are due on the maturity date. The loans may be voluntarily prepaid in whole or in part without premium or penalty and have a maturity date of May 7, 2019. The loans are subject to an interest rate equal to LIBOR or a fluctuating rate as defined by the loan agreement, at the Company’s discretion, plus an applicable rate. The applicable rate is based upon the Company’s consolidated leverage ratio, as defined in the loan agreement, and the interest rate was 2.27% at December 31, 2016. The Company has $81,000 of undrawn revolving loan at December 31, 2016 that is subject to a commitment fee, which is based on the Company’s consolidated leverage ratio as defined in the loan agreement. The loan agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated fixed charge coverage ratio to exceed a certain minimum ratio. At December 31, 2016, the Company was in compliance with these covenants. Indebtedness under the Company’s loan agreements are secured by assets of the company. The following table summarizes the future minimum debt payments as of December 31, 2016: Year Term loan Revolving loan Total 2017 $ 35,000 $ - $ 35,000 2018 35,000 - 35,000 2019 192,500 19,000 211,500 Future principle payments 262,500 19,000 281,500 Less unamortized debt financing costs 1,010 - 1,010 Less current portion of long-term debt 35,000 - 35,000 Total long-term debt $ 226,490 $ 19,000 $ 245,490 Costs associated with the issuance of debt instruments are capitalized as debt discount and amortized over the terms of the respective financing arrangements using the effective interest method. If debt is retired early, the related unamortized costs are expensed in the period the debt is retired. Capitalized costs net of accumulated amortization total $1,010 at December 31, 2016 and are shown net against outstanding principle on the accompanying balance sheet. Amortization expense pertaining to these costs totaled $526 and $603 for the years ended December 31, 2016 and 2015, respectively, and is included in interest expense in the accompanying condensed consolidated statements of earnings. |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2016 | |
INCOME TAXES [Abstract] | |
INCOME TAXES | NOTE 9 - INCOME TAXES Income tax expense consists of the following: 2016 2015 2014 Current: Federal $ 28,765 $ 29,638 $ 25,937 Foreign 2,670 3,021 2,141 State 2,483 2,982 2,412 Deferred: Federal (7,114 ) (6,815 ) (5,772 ) Foreign 52 58 85 State 106 (1,543 ) (577 ) Total income tax provision $ 26,962 $ 27,341 $ 24,226 The provision for income taxes differs from the amount computed by applying the Federal statutory rate of 35% to earnings before income tax expense due to the following: 2016 2015 2014 Income tax at Federal statutory rate $ 29,027 $ 30,471 26,968 State income taxes, net of Federal income taxes 1,510 556 1,182 Domestic production activities deduction (3,299 ) (2,709 ) (2,567 ) Other (276 ) (977 ) (1,357 ) Total income tax provision $ 26,962 $ 27,341 24,226 The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2016 and 2015 were as follows: 2016 2015 Deferred tax assets: Inventories $ 2,378 $ 1,432 Restricted stock and stock options 5,100 4,956 Other 2,629 807 Total deferred tax assets 10,107 7,195 Deferred tax liabilities: Amortization $ 56,111 $ 49,726 Depreciation 27,435 22,464 Prepaid expense - 658 Other 48 752 Total deferred tax liabilities 83,594 73,600 Net deferred tax liability $ 73,487 $ 66,405 There is no valuation allowance for deferred tax assets at December 31, 2016 and 2015. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, management believes it is more likely than not the Company will realize the benefits of these deductible differences. The amount of deferred tax asset realizable, however, could change if management’s estimate of future taxable income should change. Provisions of ASC 740-10 clarify whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, which is included in other long-term obligations on the Company’s consolidated balance sheets, is as follows: 2016 2015 2014 Balance at beginning of period $ 6,570 $ 5,205 $ 3,076 Increases for tax positions of prior years 332 943 1,922 Decreases for tax positions of prior years (406 ) (120 ) (417 ) Increases for tax positions related to current year 141 542 624 Balance at end of period $ 6,637 $ 6,570 $ 5,205 All of the Company’s unrecognized tax benefits, if recognized in future periods, would impact the Company’s effective tax rate in such future periods. The Company recognizes both interest and penalties as part of the income tax provision. During the years ended December 31, 2016, 2015 and 2014, the Company recognized approximately $94, $138 and $37 in interest and penalties, respectively. As of December 31, 2016 and 2015, accrued interest and penalties were $2,486 and 2,405, respectively. The Company files income tax returns in the U.S. and in various states and foreign countries. In the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2012. The Company does not anticipate any material change in the total amount of unrecognized tax benefits to occur within the next twelve months. |
NET EARNINGS PER COMMON SHARE
NET EARNINGS PER COMMON SHARE | 12 Months Ended |
Dec. 31, 2016 | |
NET EARNINGS PER COMMON SHARE [Abstract] | |
NET EARNINGS PER COMMON SHARE | NOTE 10 - NET EARNINGS PER COMMON SHARE The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per common share: 2016 Earnings (Numerator) Number of Shares (Denominator) Per Share Amount Basic EPS – Net earnings and weighted average common shares outstanding $ 55,972 31,521,667 $ 1.78 Effect of dilutive securities – stock options, restricted stock, and performance shares 400,971 Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock $ 55,972 31,922,638 $ 1.75 2015 Earnings (Numerator) Number of Shares (Denominator) Per Share Amount Basic EPS – Net earnings and weighted average common shares outstanding $ 59,722 31,158,142 $ 1.92 Effect of dilutive securities – stock options, restricted stock, and performance shares 477,496 Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock $ 59,722 31,635,638 $ 1.89 2014 Earnings (Numerator) Number of Shares (Denominator) Per Share Amount Basic EPS – Net earnings and weighted average common shares outstanding $ 52,826 30,381,310 $ 1.74 Effect of dilutive securities – stock options and restricted stock 790,412 Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock $ 52,826 31,171,722 $ 1.69 The Company had 2,500, 194,372, and 56,500 stock options outstanding at December 31, 2016, 2015 and 2014, respectively that could potentially dilute basic earnings per share in future periods that were not included in diluted earnings per share because their effect on the period presented was anti-dilutive. The Company has some share-based payment awards that have non-forfeitable dividend rights. These awards are restricted shares and they participate on a one-for-one basis with holders of Common Stock. These awards have an immaterial impact as participating securities with regard to the calculation using the two-class method for determining earnings per share. |
EMPLOYEE BENEFIT PLANS
EMPLOYEE BENEFIT PLANS | 12 Months Ended |
Dec. 31, 2016 | |
EMPLOYEE BENEFIT PLANS [Abstract] | |
EMPLOYEE BENEFIT PLANS | NOTE 11 - EMPLOYEE BENEFIT PLANS During 2016, the Company sponsored two 401(k) savings plans for eligible employees. The plans allow participants to make pretax contributions and the Company matches certain percentages of those pretax contributions. The plans have a discretionary profit sharing portion and one of the plans matches 401k contributions with shares of the Company’s Common Stock. All amounts contributed to the plans are deposited into a trust fund administered by independent trustees. These plans were merged in January 2017. The merged plan allows participants to make pretax contributions and the Company matches certain percentages of those contributions which is made with shares of the Company’s stock. Additionally, this plan has a discretionary profit sharing portion. The Company provided for profit sharing contributions and matching 401(k) savings plan contributions of $712 and $2,248 in 2016, $738 and $1,886 in 2015, and $938 and $804 in 2014, respectively. The Company also provides postretirement benefits in the form of an unfunded retirement medical plan under a collective bargaining agreement covering eligible retired employees of the Verona facility. The Company uses a December 31 measurement date for its postretirement medical plan. In accordance with ASC 715, “Compensation—Retirement Benefits,” the Company is required to recognize the over funded or underfunded status of a defined benefit post retirement plan (other than a multiemployer plan) as an asset or liability in its statement of financial position, and to recognize changes in that funded status in the year in which the changes occur through comprehensive income. In addition, during 2016 the Company adopted an unfunded postretirement medical plan for Named Executive Officers. The actuarial recorded liabilities for such unfunded postretirement benefits are as follows: Change in benefit obligation: 2016 2015 Benefit obligation at beginning of year $ 958 $ 1,111 Initial adoption of new plan 444 - Service cost with interest to end of year 66 54 Interest cost 48 36 Participant contributions 5 5 Benefits paid (9 ) (6 ) Actuarial gain (101 ) (242 ) Benefit obligation at end of year $ 1,411 $ 958 Change in plan assets: 2016 2015 Fair value of plan assets at beginning of year $ - $ - Employer (reimbursement)/contributions 4 1 Participant contributions 5 5 Benefits paid (9 ) (6 ) Fair value of plan assets at end of year $ - $ - Amounts recognized in consolidated balance sheet: 2016 2015 Accumulated postretirement benefit obligation $ (1,411 ) $ (958 ) Fair value of plan assets - - Funded status (1,411 ) (958 ) Unrecognized prior service cost N/A N/A Unrecognized net (gain)/loss N/A N/A Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations) $ 1,411 $ 958 Accrued postretirement benefit cost (included in other long-term obligations) $ N/A $ N/A Components of net periodic benefit cost: 2016 2015 2014 Service cost with interest to end of year $ 66 $ 54 $ 57 Interest cost 48 36 48 Amortization of prior service credit/(cost) 57 (18 ) (18 ) Amortization of (gain)/loss (10 ) - 6 Total net periodic benefit cost $ 161 $ 72 $ 93 Estimated future employer contributions and benefit payments are as follows: Year 2017 $ 88 2018 106 2019 96 2012 90 2021 88 Years 2022-2026 581 Assumed health care cost trend rates have been used in the valuation of postretirement health insurance benefits. The trend rate is 7.07% in 2016 declining to 4.50% in 2038 and thereafter. A one percentage point increase in health care cost trend rates in each year would increase the accumulated postretirement benefit obligation as of December 31, 2016 by $125 and the net periodic postretirement benefit cost for 2016 by $15. A one percentage point decrease in health care cost trend rates in each year would decrease the accumulated postretirement benefit obligation as of December 31, 2016 by $110 and the net periodic postretirement benefit cost for 2016 by $13. The weighted average discount rate used in determining the accumulated postretirement benefit obligation was 3.40% in 2016 and 3.70% in 2015. The Company contributes to one multiemployer defined benefit plan under the terms of a collective-bargaining agreement covering its union-represented employees of the Verona facility. The risks of participation in this multiemployer plan are different from single-employer plans in the following aspects: (a) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers, (b) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers, and (c) if the Company chooses to stop participating in its multiemployer plan, the Company will be required to pay that plan an amount based on the underfunded status of the plan, referred to as the withdrawal liability. The Company’s participation in this plan for the annual period ended December 31, 2016 is outlined in the table below. The “EIN/Pension Plan Number” column provides the Employee Identification Number (EIN). The zone status is based on information that the Company received from the plan and is certified by the plan’s actuary. Among other factors, plans in the red zone are generally less than 65 percent funded, plans in the yellow zone are less than 80 percent funded, and plans in the green zone are at least 80 percent funded. The “FIP/RP Status Pending/Implemented” column indicates plans for which a financial improvement plan (FIP) or a rehabilitation plan (RP) is either pending or has been implemented. The last column lists the expiration date of the collective-bargaining agreement to which the plan is subject. Finally, the period-to-period comparability of the contributions for 2016 and 2015 was affected by a 4.0% increase in the 2016 contribution rate. There have been no other significant changes that affect the comparability of 2016 and 2015 contributions. The Company does not represent more than 5% of the contributions to this pension fund. Pension EIN/Pension Plan Pension Plan Protection Act FIP/RP Status Pending/ Contributions of Balchem Corporation Surcharge Imposed Expiration Date 2016 2015 2016 2015 2014 Central States, Southeast and Southwest Areas Pension Fund 36-6044243 Red as of 1/1/2016 Red as of 1/1/2015 Implemented $ 576 $ 515 $ 498 No 5/31/2017 |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2016 | |
COMMITMENTS AND CONTINGENCIES [Abstract] | |
COMMITMENTS AND CONTINGENCIES | NOTE 12 - COMMITMENTS AND CONTINGENCIES In 2012, the Company entered into a six (6) year lease extension for approximately 20,000 square feet of office space. The office space serves as the Company’s general offices and as a laboratory facility. The Company leases most of its vehicles and office equipment under non-cancelable operating leases, which expire at various times through 2029. Rent expense charged to operations under such lease agreements for 2016, 2015 and 2014 aggregated approximately $3,134, $2,414 and $1,595, respectively. Aggregate future minimum rental payments required under non-cancelable operating leases at December 31, 2016 are as follows: Year 2017 $ 2,436 2018 2,011 2019 1,702 2020 1,364 2021 1,245 Thereafter 8,752 Total minimum lease payments $ 17,510 In 1982, the Company discovered and thereafter removed a number of buried drums containing unidentified waste material from the Company’s site in Slate Hill, New York. The Company thereafter entered into a Consent Decree to evaluate the drum site with the New York Department of Environmental Conservation (“NYDEC”) and performed a Remedial Investigation/Feasibility Study that was approved by NYDEC in February 1994. Based on NYDEC requirements, the Company cleaned the area and removed soil from the drum burial site, which was completed in 1996. The Company continues to be involved in discussions with NYDEC to evaluate test results and determine what, if any, additional actions will be required on the part of the Company to close out the remediation of this site. Additional actions, if any, would likely require the Company to continue monitoring the site. The cost of such monitoring has been less than $5 per year for the period 2004 to date. The Company’s Verona, Missouri facility, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983, because of dioxin contamination on portions of the site. Remediation conducted by the prior owner under the oversight of the EPA and the Missouri Department of Natural Resources (“MDNR”) included removal of dioxin contaminated soil and equipment, capping of areas of residual contamination in four relatively small areas of the site separate from the manufacturing facilities, and the installation of wells to monitor groundwater and surface water contamination by organic chemicals. No ground water or surface water treatment was required. The Company believes that remediation of the site is complete. In 1998, the EPA certified the work on the contaminated soils to be complete. In February 2000, after the conclusion of two years of monitoring groundwater and surface water, the former owner submitted a draft third party risk assessment report to the EPA and MDNR recommending no further action. The prior owner is awaiting the response of the EPA and MDNR to the draft risk assessment. While the Company must maintain the integrity of the capped areas in the remediation areas on the site, the prior owner is responsible for completion of any further Superfund remedy. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for potential liabilities associated with the Superfund site and one of the sellers, in turn, has the benefit of certain contractual indemnification by the prior owner that is implementing the above-described Superfund remedy. From time to time, the Company is a party to various litigation, claims and assessments. Management believes that the ultimate outcome of such matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity. |
FAIR VALUE OF FINANCIAL INSTRUM
FAIR VALUE OF FINANCIAL INSTRUMENTS | 12 Months Ended |
Dec. 31, 2016 | |
FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract] | |
FAIR VALUE OF FINANCIAL INSTRUMENTS | NOTE 13 – FAIR VALUE OF FINANCIAL INSTRUMENTS The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at December 31, 2016 and December 31, 2015 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying condensed consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable, and accrued liabilities, which are carried at cost and approximates fair value due to the short-term maturity of these instruments. Cash and cash equivalents at December 31, 2016 and 2015 includes $776 and $773 in money market funds. The money market funds are valued using level one inputs, as defined by ASC 820, “Fair Value Measurement.” |
ACCUMULATED OTHER COMPREHENSIVE
ACCUMULATED OTHER COMPREHENSIVE INCOME | 12 Months Ended |
Dec. 31, 2016 | |
ACCUMULATED OTHER COMPREHENSIVE INCOME [Abstract] | |
ACCUMULATED OTHER COMPREHENSIVE INCOME | NOTE 14 – ACCUMULATED OTHER COMPREHENSIVE INCOME The changes in accumulated other comprehensive income (loss) were as follows: 2016 Years Ended December 31, 2015 2014 Net foreign currency translation adjustment $ (1,390 ) $ (2,615 ) $ (2,972 ) Net change in postretirement benefit plan (see Note 10 for further information) Initial adoption of new plan (444 ) - - Net gain arising during the period 101 242 191 Amortization of prior service credit/(cost) 57 (18 ) (18 ) Amortization of (gain)/loss (10 ) - 6 Total before tax (296 ) 224 179 Tax (49 ) (72 ) (56 ) Net of tax (345 ) 152 123 Total other comprehensive income (loss) $ (1,735 ) $ (2,463 ) $ (2,849 ) Accumulated other comprehensive income/(loss) at December 31, 2016 consisted of the following: Foreign currency translation adjustment Postretirement benefit plan Total Balance December 31, 2015 $ (5,317 ) $ 203 $ (5,114 ) Other comprehensive (loss)/gain (1,390 ) (345 ) (1,735 ) Balance December 31, 2016 $ (6,707 ) $ (142 ) $ (6,849 ) |
SEGMENT INFORMATION
SEGMENT INFORMATION | 12 Months Ended |
Dec. 31, 2016 | |
SEGMENT INFORMATION [Abstract] | |
SEGMENT INFORMATION | NOTE 15 - SEGMENT INFORMATION Human Nutrition & Health (formerly SensoryEffects) Our Human Nutrition & Health segment supplies ingredients in the food and beverage industry, providing customized solutions in powder, solid and liquid flavor delivery systems, spray dried emulsified powder systems, and cereal systems. Our products include creamer systems, dairy replacers, powdered fats, nutritional beverage bases, beverages, juice & dairy bases, chocolate systems, ice cream bases & variegates, ready-to-eat cereals, grain based snacks, and cereal based ingredients. Additionally, we provide microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, and nutritional supplements. We also produce and market human grade choline nutrients and mineral amino acid chelated products through this segment for wellness applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. Our mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products. Science and patented technology have been combined to create an organic molecule in a form the body can readily assimilate. Animal Nutrition & Health Our Animal Nutrition & Health (“ANH”) segment provides nutritional products derived from our microencapsulation and chelation technologies in addition to basic choline chloride. For ruminant animals, our microencapsulated products boost health and milk production, delivering nutrient supplements that are biologically available, providing required nutritional levels. Our proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. Choline deficiency can result in reduced growth and perosis in poultry, and fatty liver, kidney necrosis and general poor health condition in swine. Sales of specialty products for the animal nutrition and health industry are highly dependent on dairy industry economics as well as the ability of the Company to leverage the results of university and field research on the animal health benefits of the Company’s products. Management believes that success in the commodity-oriented basic choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to increase production efficiencies in order to maintain its competitive-cost position to effectively compete in a competitive global marketplace. Specialty Products Ethylene oxide, at the 100% level, is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. Our 100% ethylene oxide product is distributed in uniquely designed, recyclable, double-walled, stainless steel drums to assure compliance with safety, quality and environmental standards as outlined by the EPA and the DOT. Our inventory of these specially built drums, along with our two filling facilities, represents a significant capital investment. Contract sterilizers and medical device manufacturers are principal customers for this product. We also sell single use canisters with 100% ethylene oxide for use in sterilizing re-usable devices typically processed in autoclave units in hospitals. As a fumigant, ethylene oxide blends are highly effective in killing bacteria, fungi, and insects in spices and other seasoning materials. Propylene oxide is marketed and sold as a fumigant to aid in the control of insects and microbiological spoilage; and to reduce bacterial and mold contamination in certain shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes. We distribute our propylene oxide product primarily in recyclable, single-walled, carbon steel cylinders according to standards outlined by the EPA and the DOT. Our inventory of these cylinders also represents a significant capital investment. Propylene oxide is also sold to customers seeking smaller (as opposed to bulk) quantities and whose requirements include utilization in various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings. Our micronutrient agricultural nutrition business sells chelated minerals primarily into high value crops. We have a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life. First, we determine optimal mineral balance for plant health. We then have a foliar applied Metalosate product range, utilizing patented amino acid chelate technology. Our products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances. Industrial Products Certain derivatives of choline chloride are manufactured and sold into industrial applications predominately as a component for hydraulic fracturing of shale natural gas wells. Our products offer an attractive, effective and more environmentally responsible alternative than other clay stabilizers. Industrial grade choline bicarbonate is completely chloride free and our choline chloride reduces the amount of chlorides released into the environment up to 75% when compared to potassium chloride. The Industrial Products segment also includes the manufacture and sale of methylamines. Methylamines are a primary building block for the manufacture of choline products and are produced at our Italian operation and sold for a wide range of industrial applications in Europe. Business Segment Net Sales: 2016 2015 2014 Human Nutrition & Health $ 297,134 $ 278,288 $ 206,101 Animal Nutrition & Health 161,119 165,763 176,477 Specialty Products 70,126 54,236 54,053 Industrial Products 24,825 54,205 104,752 Total $ 553,204 $ 552,492 $ 541,383 Business Segment Earnings Before Income Taxes: 2016 2015 2014 Human Nutrition & Health $ 38,156 $ 38,302 $ 21,260 Animal Nutrition & Health 28,686 27,851 23,687 Specialty Products 22,862 23,995 21,316 Industrial Products 1,949 5,594 16,532 Unallocated equity compensation - (1,462 ) - Transaction costs, integration costs and legal settlement (815 ) (324 ) (652 ) Interest and other income, net (7,904 ) (6,893 ) (5,091 ) Total $ 82,934 $ 87,063 $ 77,052 Unallocated equity compensation expense was related to the accelerated vesting of previously-granted unvested options to purchase Company common stock, and removal of the restrictions on previously-granted Restricted Stock. Transaction and integration costs were primarily related to the definitive agreement to acquire Albion International, Inc. in 2016 and 2015, and Performance Chemicals & Ingredients Company (d/b/a SensoryEffects) in 2015 and 2014. See Note 2. Depreciation/Amortization: 2016 2015 2014 Human Nutrition & Health $ 33,796 $ 30,537 $ 20,873 Animal Nutrition & Health 7,243 6,573 6,026 Specialty Products 3,787 1,225 1,385 Industrial Products 850 1,027 1,783 Total $ 45,676 $ 39,362 $ 30,067 Business Segment Assets: 2016 2015 2014 Human Nutrition & Health $ 709,337 $ 642,929 $ 656,130 Animal Nutrition & Health 121,860 107,459 90,650 Specialty Products 64,030 24,769 24,913 Industrial Products 10,477 16,191 32,330 Other Unallocated 42,922 88,338 57,508 Total $ 948,626 $ 879,686 $ 861,531 Other unallocated assets consist of certain cash, receivables, prepaid expenses, equipment and leasehold improvements, net of accumulated depreciation, and deferred income taxes, which the Company does not allocate to its individual business segments. Capital Expenditures: 2016 2015 2014 Human Nutrition & Health $ 14,470 $ 21,361 $ 3,475 Animal Nutrition & Health 6,577 17,854 7,383 Specialty Products 1,286 940 896 Industrial Products 701 1,145 1,445 Total $ 23,034 $ 41,300 $ 13,199 Geographic Revenue Information: 2016 2015 2014 United States $ 420,821 $ 441,664 $ 420,324 Foreign Countries 132,383 110,828 121,059 Total $ 553,204 $ 552,492 $ 541,383 Geographic Area Data – Long-Lived Assets (excluding intangible assets): 2016 2015 2014 North America $ 154,007 $ 148,209 $ 121,090 Europe 11,747 10,306 10,498 Total $ 165,754 $ 158,515 $ 131,588 |
SUPPLEMENTAL CASH FLOW INFORMAT
SUPPLEMENTAL CASH FLOW INFORMATION | 12 Months Ended |
Dec. 31, 2016 | |
SUPPLEMENTAL CASH FLOW INFORMATION [Abstract] | |
SUPPLEMENTAL CASH FLOW INFORMATION | NOTE 16 - SUPPLEMENTAL CASH FLOW INFORMATION Cash paid during the year for: 2016 2015 2014 Income taxes $ 30,741 $ 19,551 $ 25,304 Interest $ 6,669 $ 5,987 $ 4,685 Non-cash financing activities: 2016 2015 2014 Dividends payable $ 12,088 $ 10,727 $ 9,251 |
QUARTERLY FINANCIAL INFORMATION
QUARTERLY FINANCIAL INFORMATION (UNAUDITED) | 12 Months Ended |
Dec. 31, 2016 | |
QUARTERLY FINANCIAL INFORMATION (UNAUDITED) [Abstract] | |
QUARTERLY FINANCIAL INFORMATION (UNAUDITED) | NOTE 17 - QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (In thousands, except per share data) 2016 2015 First Quarter Second Quarter Third Quarter Fourth Quarter First Quarter Second Quarter Third Quarter Fourth Quarter Net sales $ 135,141 $ 138,794 $ 138,509 $ 140,760 $ 144,862 $ 134,773 $ 140,128 $ 132,729 Gross profit 42,824 46,449 44,656 46,932 43,130 41,867 43,174 39,926 Earnings before income taxes 17,981 21,383 20,771 22,799 23,085 22,167 21,189 20,623 Net earnings 11,886 14,150 14,012 15,924 15,172 14,916 13,976 15,659 Basic net earnings per common share $ .38 $ .45 $ .44 $ .51 $ .49 $ .48 $ .45 $ .50 Diluted net earnings per common share $ .37 $ .44 $ .44 $ .50 $ .48 $ .47 $ .44 $ .49 |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 12 Months Ended |
Dec. 31, 2016 | |
RELATED PARTY TRANSACTIONS [Abstract] | |
RELATED PARTY TRANSACTIONS | NOTE 18 – RELATED PARTY TRANSACTIONS The Company provides services on a contractual agreement to St. Gabriel CC Company, LLC. These services include accounting, information technology, quality control, and purchasing services, as well as operation of the St. Gabriel CC Company, LLC plant. The Company also sold raw materials to St. Gabriel CC Company, LLC. In return, St. Gabriel CC Company, LLC provides choline chloride finished goods. The services the Company provided and raw materials sold amounted to $1,837 and $7,480, respectively, for the year ended December 31, 2016, and are primarily recorded, net of the finished goods received from St. Gabriel CC Company, LLC of $8,619, in cost of goods sold. At December 31, 2016, the Company had a receivable of $9,317, recorded in accounts receivables from St. Gabriel CC Company, LLC for services rendered and raw materials sold and a payable of $8,619 for finished goods received. In addition, the Company had a receivable in the amount of $515 related to non-contractual monies owed from St. Gabriel CC Company, LLC, recorded in other current assets. |
Valuation and Qualifying Accoun
Valuation and Qualifying Accounts | 12 Months Ended |
Dec. 31, 2016 | |
Valuation and Qualifying Accounts [Abstract] | |
Valuation and Qualifying Accounts | BALCHEM CORPORATION Valuation and Qualifying Accounts Years Ended December 31, 2016, 2015 and 2014 (In thousands) Description Balance at Beginning of Year Additions Charged (Credited) to Costs and Expenses Deductions Balance at End of Year Year ended December 31, 2016 Allowance for doubtful accounts $ 235 $ 417 $ (163 ) (a) $ 489 Inventory reserve 1,823 905 (182 ) (a) 2,546 Year ended December 31, 2015 Allowance for doubtful accounts $ 288 $ (1 ) $ (52 ) (a) $ 235 Inventory reserve 1,682 369 (228 ) (a) 1,823 Year ended December 31, 2014 Allowance for doubtful accounts $ 115 $ 238 $ (65 ) (a) $ 288 Inventory reserve 181 2,073 (572 ) (a) 1,682 (a) represents write-offs. |
BUSINESS DESCRIPTION AND SUMM29
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2016 | |
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] | |
Principles of Consolidation | Principles of Consolidation The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. |
Revenue Recognition | Revenue Recognition Revenue for each of our business segments is recognized upon product shipment, passage of title and risk of loss, and when collection is reasonably assured. The Company reports amounts billed to customers related to shipping and handling as revenue and includes costs incurred for shipping and handling in cost of sales. Amounts received for unshipped merchandise are not recognized as revenue but rather they are recorded as customer deposits and are included in current liabilities. In instances of shipments made on consignment, revenue is deferred until a customer indicates to the Company that it has used the Company’s products. The Company does not charge its customers rental fees on cylinders or drums used to ship its products. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents. The Company has |
Accounts Receivable | Accounts Receivable Credit terms are granted in the normal course of business to our customers. On-going credit evaluations are performed on our customers and credit limits are adjusted based upon payment history and the customer's current credit worthiness, as determined through review of their current credit information. Collections and payments from customers are continuously monitored and allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments are maintained. Estimated losses are based on historical experience and any specific customer collection issues identified. |
Inventories | Inventories Inventories are valued at the lower of cost (first in, first out or average) or market value and have been reduced by an allowance for excess or obsolete inventories. Cost elements include material, labor and manufacturing overhead. |
Property, Plant and Equipment and Depreciation | Property, Plant and Equipment and Depreciation Property, plant and equipment are stated at cost. Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows: Buildings 15-25 Equipment 2-28 years Expenditures for repairs and maintenance are charged to expense. Alterations and major overhauls that extend the lives or increase the capacity of plant assets are capitalized. When assets are retired or otherwise disposed of, the cost of the assets and the related accumulated depreciation are removed from the accounts and any resultant gain or loss is included in earnings. |
Business Concentrations | Business Concentrations Financial instruments that subject the Company to credit risk consist primarily of accounts receivable and money market investments. Investments are managed within established guidelines to mitigate risks. Accounts receivable subject the Company to credit risk partially due to the concentration of amounts due from customers. The Company extends credit to its customers based upon an evaluation of the customers’ financial condition and credit histories. The majority of the Company’s customers are major national or international corporations. In 2016, 2015 and 2014, no customer accounted for more than 10% of total net sales. |
Goodwill and Acquired Intangible Assets | Goodwill and Acquired Intangible Assets Goodwill represents the excess of costs over fair value of assets of businesses acquired. ASC 350, “Intangibles-Goodwill and Other,” requires the use of the acquisition method of accounting for a business combination and defines an intangible asset. Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized, but are instead assessed for impairment annually and more frequently if events and circumstances indicate that the asset might be impaired, in accordance with the provisions of ASC 350. The Company performs its annual test as of October 1. ASC 350 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment if events and circumstances indicate that the asset might be impaired. In accordance with ASU No. 2011-08, “Intangibles—Goodwill and Other (Topic 350): Testing Goodwill for Impairment” (“ASU 2011-08”) As of October 1, 2016 and 2015, the Company opted to bypass the qualitative assessment and proceeded directly to performing the first step of the goodwill impairment test. We assessed the fair values of our reporting units by utilizing the income approach, based on a discounted cash flow valuation model as the basis for our conclusions, as well as market approaches for certain reporting units. Our estimates of future cash flows included significant management assumptions such as revenue growth rates, operating margins, discount rates, estimated terminal values and future economic and market conditions. Our assessment concluded that the fair values of the reporting units exceeded their carrying amounts, including goodwill. Accordingly, the goodwill of the reporting units is not considered impaired. The Company may resume performing the qualitative assessment in subsequent periods. The Company had goodwill in the amount of $439,811 and $383,906 as of December 31, 2016 and December 31, 2015, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” Goodwill at January 1, 2016 $ 383,906 Goodwill as a result of the Acquisition of Albion International, Inc. – see Note 2 55,905 Goodwill at December 31, 2016 $ 439,811 There was a $4,272 reduction in the carrying amount of goodwill during the three months ended December 31, 2016, as a result of changes to the fair value of assets acquired December 31, 2016 December 31, 2015 Human Nutrition & Health $ 404,187 $ 363,784 Animal Nutrition & Health 11,734 11,734 Specialty Products 22,662 7,160 Industrial Products 1,228 1,228 Total $ 439,811 $ 383,906 The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives: Amortization Period Customer relationships and lists 10 Trademarks & trade names 17 Developed technology 5 Regulatory registration costs 5 - 10 Patents & trade secrets 15 - 17 Other 5 - 10 For the year ended December 31, 2016, there were no triggering events which required intangible asset impairment reviews. |
Income Taxes | Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. |
Use of Estimates | Use of Estimates Management of the Company is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and revenues and expenses during the reporting period. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Actual results could differ from those estimates. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at December 31, 2016 and 2015 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable and accrued liabilities, and are carried at cost which approximates fair value due to the short-term maturity of these instruments. |
Cost of Sales | Cost of Sales Cost of sales are primarily comprised of raw materials and supplies consumed in the manufacture of product, as well as manufacturing labor, maintenance labor, depreciation expense, and direct overhead expense necessary to convert purchased materials and supplies into finished product. Cost of sales also includes inbound freight costs, outbound freight costs for shipping products to customers, warehousing costs, quality control and obsolescence expense. |
Selling, General and Administrative Expenses | Selling, General and Administrative Expenses Selling expenses consist primarily of compensation and benefit costs, amortization of customer relationships and lists, trade promotions, advertising, commissions and other marketing costs. General and administrative expenses consist primarily of payroll and benefit costs, occupancy and operating costs of corporate offices, depreciation and amortization expense on non-manufacturing assets, information systems costs and other miscellaneous administrative costs. |
Research and Development | Research and Development Research and development costs are expensed as incurred. |
Net Earnings Per Common Share | Net Earnings Per Common Share Basic net earnings per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share is calculated in a manner consistent with basic net earnings per common share except that the weighted average number of common shares outstanding also includes the dilutive effect of stock options outstanding, unvested restricted stock, and unvested performance shares (using the treasury stock method). |
Stock-based Compensation | Stock-based Compensation The Company has stock-based employee compensation plans, which are described more fully in Note 3. The Company accounts for stock-based compensation in accordance with ASC 718, “Compensation-Stock Compensation,” which requires all share-based payments, including grants of stock options, to be recognized in the income statement as an operating expense, based on their fair values. The Company estimates the fair value of each option award on the date of grant using a Black-Scholes based option-pricing model. Estimates of and assumptions about forfeiture rates, terms, volatility, interest rates and dividend yields are used to calculate stock-based compensation. A significant change to these estimates could materially affect the Company’s operating results. |
Impairment of Long-lived Assets | Impairment of Long-lived Assets Long-lived assets, such as property, plant, and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is generally based on discounted cash flows. |
New Accounting Pronouncements | New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), with amendments issued in 2016, which addresses revenue recognition issues and, upon its effective date, replaces almost all existing revenue recognition guidance, including industry-specific guidance, in current U.S. GAAP. This standard is effective, with either a full retrospective approach or a modified retrospective approach, for annual and interim periods beginning after December 15, 2017. We are assessing the impact of the guidance on our current accounting practices to identify differences that would result from applying the new requirements to our revenue contracts. We continue to make significant progress on our contract reviews and are also still in the process of evaluating the impact, if any, on changes to our business processes, systems, and controls to support recognition and disclosure under the new guidance. Based on our findings so far, we do not currently expect this guidance to have a material impact on our financial statements. We are continuing our implementation plan and currently expect to adopt the new guidance beginning in 2018 using the modified retrospective approach. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory” (“ASU 2015-11”), which requires inventory to be measured at the lower of cost and net realizable value. This standard is effective prospectively for annual and interim periods beginning after December 15, 2016. Although, early adoption is permitted, the Company has elected not to adopt early as this ASU will not have a significant impact on the Company’s consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), to simplify the presentation of deferred income taxes. The ASU requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This standard is effective prospectively for annual and interim periods beginning after December 15, 2016. Although, early adoption is permitted, the Company has elected not to adopt early as this ASU will not have a significant impact on the Company’s consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases” (“ASU 2016-02”), which addresses the recognition of assets and liabilities that arise from all leases. The guidance requires lessees to recognize right-to-use assets and lease liabilities for most leases in the Consolidated Balance Sheets. The guidance is effective for annual and interim periods beginning after December 15, 2018 and early adoption is permitted. The Company is currently evaluating the impact of the new guidance. In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”), which addresses the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for annual and interim periods beginning after December 15, 2016. Although, early adoption is permitted, the Company has elected not to adopt early. We expect that the adoption of this new guidance in 2017 will reduce our reported income taxes and will increase cash flows from operating activities; however, the amounts of that reduction/increase is dependent upon the underlying vesting or exercise activity and related future stock prices. In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business” (“ASU 2017-01”), which addresses the definition of what constitutes a business by providing clarification of the three elements that constitutes a business. The guidance is effective for annual and interim periods beginning after December 15, 2017. Although, early adoption is permitted, the Company has elected not to adopt early as this ASU will not have a significant impact on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Although, early adoption is permitted, the Company has elected not to adopt early as this ASU will not have a significant impact on the Company’s consolidated financial statements. |
Reclassifications | Reclassifications Certain reclassifications have been made to the prior years’ financial statements to conform to the current year’s presentation with no impact on net earnings or stockholders’ equity. |
BUSINESS DESCRIPTION AND SUMM30
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] | |
Property, plant and equipment, estimated useful lives | Depreciation of plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows: Buildings 15-25 Equipment 2-28 years |
Summary of goodwill | The Company had goodwill in the amount of $439,811 and $383,906 as of December 31, 2016 and December 31, 2015, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” Goodwill at January 1, 2016 $ 383,906 Goodwill as a result of the Acquisition of Albion International, Inc. – see Note 2 55,905 Goodwill at December 31, 2016 $ 439,811 There was a $4,272 reduction in the carrying amount of goodwill during the three months ended December 31, 2016, as a result of changes to the fair value of assets acquired December 31, 2016 December 31, 2015 Human Nutrition & Health $ 404,187 $ 363,784 Animal Nutrition & Health 11,734 11,734 Specialty Products 22,662 7,160 Industrial Products 1,228 1,228 Total $ 439,811 $ 383,906 |
Intangible assets, estimated useful lives | The following intangible assets with finite lives are stated at cost and are amortized either on an accelerated basis or on a straight-line basis over the following estimated useful lives: Amortization Period Customer relationships and lists 10 Trademarks & trade names 17 Developed technology 5 Regulatory registration costs 5 - 10 Patents & trade secrets 15 - 17 Other 5 - 10 |
ACQUISITION (Tables)
ACQUISITION (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
ACQUISITIONS [Abstract] | |
Estimated fair values of the assets acquired and liabilities assumed | The following table summarizes the fair values of the assets acquired and liabilities assumed. Cash and cash equivalents $ $ 4,949 Accounts receivable 7,671 Inventories 15,989 Property, plant and equipment 7,217 Customer relationships 18,443 Developed technology 9,060 Trade name 7,224 Licensing agreements 6,658 Other assets 1,200 Trade accounts payable (1,104 ) Accrued expenses (2,788 ) Bank debt (884 ) Deferred income taxes (13,990 ) Goodwill 55,905 Amount paid to shareholders 115,550 Albion bank debt paid on purchase date 884 Total amount paid on acquisition date $ $ 116,434 |
Acquisition of unaudited pro forma information | The following unaudited pro forma information has been prepared as if the Acquisition had occurred on January 1, 2015. Year Ended December 31, 2016 Year Ended December 31, 2015 Net Sales Net Earnings Net Sales Net Earnings Albion’s actual results included in the Company’s consolidated income statement $ $49,608 $ $ 2,938 $ - $ - Supplemental pro forma combined financial information $ $557,784 $ $ 60,840 $ $ 605,273 $ $ 56,109 Basic earnings per share $ $ 1.93 $ $ 1.80 Diluted earnings per share $ $ 1.91 $ $ 1.77 |
STOCKHOLDERS' EQUITY (Tables)
STOCKHOLDERS' EQUITY (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
STOCKHOLDERS' EQUITY [Abstract] | |
Effect of compensation cost on earnings | The Company’s results for the years ended December 31, 2016, 2015 and 2014 reflected the following compensation cost and such compensation cost had the following effects on net earnings: Increase/(Decrease) for the Years Ended December 31, 2016 2015 2014 Cost of sales $ 1,040 $ 854 $ 593 Operating expenses 5,984 5,975 3,964 Net earnings (4,473 ) (4,395 ) (2,926 ) |
Assumptions used in the valuation of option awards | The fair value of each option award issued under the 1999 Stock Plan is estimated on the date of grant using a Black-Scholes based option-pricing model that uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of the Company’s stock. The expected term of the options is based on the Company’s historical experience of employees’ exercise behavior. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life. Weighted Average Assumptions: 2016 Years Ended 2015 2014 Expected Volatility 34.4 % 33.2 % 33.7 % Expected Term (in years) 5.0 5.5 5.6 Risk-Free Interest Rate 1.2 % 1.7 % 1.8 % Dividend Yield 0.5 % 0.6 % 0.5 % |
Summary of stock option activity | A summary of stock option plan activity for 2016, 2015, and 2014 for all plans is as follows: 2016 # of Shares (000s) Weighted Average Exercise Price Outstanding at beginning of year 1,017 $ 37.29 Granted 341 60.92 Exercised (236 ) 30.44 Forfeited (56 ) 58.23 Outstanding at end of year 1,066 $ 45.32 Exercisable at end of year 604 $ 34.77 2015 # of Shares (000s) Weighted Average Exercise Price Outstanding at beginning of year 1,470 $ 27.35 Granted 209 58.34 Exercised (627 ) 20.16 Forfeited (35 ) 52.97 Outstanding at end of year 1,017 $ 37.29 Exercisable at end of year 667 $ 29.19 2014 # of Shares (000s) Weighted Average Exercise Price Outstanding at beginning of year 1,893 $ 20.94 Granted 313 53.38 Exercised (610 ) 14.92 Forfeited (126 ) 56.03 Outstanding at end of year 1,470 $ 27.35 Exercisable at end of year 1,066 $ 21.52 |
Other information pertaining to stock option activity | Other information pertaining to option activity during the years ended December 31, 2016, 2015 and 2014 was as follows: Years Ended December 31, 2016 2015 2014 Weighted-average fair value of options granted $ 18.48 $ 18.35 $ 17.36 Total intrinsic value of stock options exercised ($000s) $ 8,609 $ 24,047 $ 25,224 |
Additional information relating to stock options outstanding | Additional information related to stock options outstanding under all plans at December 31, 2016 is as follows: Options Outstanding Options Exercisable Range of Exercise Prices Shares Outstanding (000s) Weighted Average Remaining Contractual Term Weighted Average Exercise Price Number Exercisable (000s) Weighted Average Exercise Price $ 13.61 - $34.81 356 3.5 years $ 25.40 356 $ 25.40 38.10 - 59.95 406 6.6 years 51.03 224 46.89 60.01 - 80.26 304 9.0 years 61.00 24 60.84 1,066 6.2 years $ 45.32 604 $ 34.77 |
Non-vested restricted stock activity | Non-vested restricted stock activity for the years ended December 31, 2016, 2015 and 2014 is summarized below: Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2015 150 $ 47.46 Granted 19 61.22 Vested (66 ) 40.96 Forfeited (1 ) 56.77 Non-vested balance as of December 31, 2016 102 $ 54.18 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2014 134 $ 38.13 Granted 77 55.77 Vested (61 ) 37.35 Forfeited - - Non-vested balance as of December 31, 2015 150 $ 47.46 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2013 172 $ 33.69 Granted 33 54.86 Vested (65 ) 34.19 Forfeited (6 ) 45.32 Non-vested balance as of December 31, 2014 134 $ 38.13 |
Non-vested performance share activity | Non-vested performance share activity for the years ended December 31, 2016, 2015 and 2014 is summarized below: Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2015 20 $ 58.77 Granted 22 63.15 Vested - - Forfeited (8 ) 60.88 Non-vested balance as of December 31, 2016 34 $ 61.06 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2014 - $ - Granted 29 58.77 Vested - - Forfeited (9 ) 58.77 Non-vested balance as of December 31, 2015 20 $ 58.77 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2013 - $ - Granted - - Vested - - Forfeited - - Non-vested balance as of December 31, 2014 - $ - |
INVENTORIES (Tables)
INVENTORIES (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
INVENTORIES [Abstract] | |
Inventories | Inventories at December 31, 2016 and 2015 consisted of the following: 2016 2015 Raw materials $ 20,751 $ 16,786 Work in progress 3,225 1,807 Finished goods 33,269 27,492 Total inventories $ 57,245 $ 46,085 |
PROPERTY, PLANT AND EQUIPMENT (
PROPERTY, PLANT AND EQUIPMENT (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
PROPERTY, PLANT AND EQUIPMENT [Abstract] | |
Property, plant and equipment | Property, plant and equipment at December 31, 2016 and 2015 are summarized as follows: 2016 2015 Land $ 4,208 $ 3,247 Building 45,735 33,051 Equipment 177,841 153,682 Construction in progress 17,357 39,525 245,141 229,505 Less: Accumulated depreciation 79,387 70,990 Property, plant and equipment, net $ 165,754 $ 158,515 |
INTANGIBLE ASSETS (Tables)
INTANGIBLE ASSETS (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
INTANGIBLE ASSETS [Abstract] | |
Intangible assets with finite lives | As of December 31, 2016 and 2015, the Company had identifiable intangible assets as follows: Amortization Period (In years) 2016 Gross Carrying Amount 2016 Accumulated Amortization 2015 Gross Carrying Amount 2015 Accumulated Amortization Customer relationships & lists 10 $ 185,885 $ 86,338 $ 167,442 $ 63,578 Trademarks & trade names 17 39,241 9,260 32,014 5,704 Developed technology 5 12,260 3,358 3,200 1,057 Other 5-17 12,713 3,659 5,102 2,508 $ 250,099 $ 102,615 $ 207,758 $ 72,847 |
LONG TERM DEBT (Tables)
LONG TERM DEBT (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
LONG TERM DEBT [Abstract] | |
Future minimum debt payments | The following table summarizes the future minimum debt payments as of December 31, 2016: Year Term loan Revolving loan Total 2017 $ 35,000 $ - $ 35,000 2018 35,000 - 35,000 2019 192,500 19,000 211,500 Future principle payments 262,500 19,000 281,500 Less unamortized debt financing costs 1,010 - 1,010 Less current portion of long-term debt 35,000 - 35,000 Total long-term debt $ 226,490 $ 19,000 $ 245,490 |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
INCOME TAXES [Abstract] | |
Income tax expense | Income tax expense consists of the following: 2016 2015 2014 Current: Federal $ 28,765 $ 29,638 $ 25,937 Foreign 2,670 3,021 2,141 State 2,483 2,982 2,412 Deferred: Federal (7,114 ) (6,815 ) (5,772 ) Foreign 52 58 85 State 106 (1,543 ) (577 ) Total income tax provision $ 26,962 $ 27,341 $ 24,226 |
Income tax reconciliation | The provision for income taxes differs from the amount computed by applying the Federal statutory rate of 35% to earnings before income tax expense due to the following: 2016 2015 2014 Income tax at Federal statutory rate $ 29,027 $ 30,471 26,968 State income taxes, net of Federal income taxes 1,510 556 1,182 Domestic production activities deduction (3,299 ) (2,709 ) (2,567 ) Other (276 ) (977 ) (1,357 ) Total income tax provision $ 26,962 $ 27,341 24,226 |
Deferred tax assets and liabilities | The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2016 and 2015 were as follows: 2016 2015 Deferred tax assets: Inventories $ 2,378 $ 1,432 Restricted stock and stock options 5,100 4,956 Other 2,629 807 Total deferred tax assets 10,107 7,195 Deferred tax liabilities: Amortization $ 56,111 $ 49,726 Depreciation 27,435 22,464 Prepaid expense - 658 Other 48 752 Total deferred tax liabilities 83,594 73,600 Net deferred tax liability $ 73,487 $ 66,405 |
Reconciliation of unrecognized tax benefits | A reconciliation of the beginning and ending amount of unrecognized tax benefits, which is included in other long-term obligations on the Company’s consolidated balance sheets, is as follows: 2016 2015 2014 Balance at beginning of period $ 6,570 $ 5,205 $ 3,076 Increases for tax positions of prior years 332 943 1,922 Decreases for tax positions of prior years (406 ) (120 ) (417 ) Increases for tax positions related to current year 141 542 624 Balance at end of period $ 6,637 $ 6,570 $ 5,205 |
NET EARNINGS PER COMMON SHARE (
NET EARNINGS PER COMMON SHARE (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
NET EARNINGS PER COMMON SHARE [Abstract] | |
Reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share | The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per common share: 2016 Earnings (Numerator) Number of Shares (Denominator) Per Share Amount Basic EPS – Net earnings and weighted average common shares outstanding $ 55,972 31,521,667 $ 1.78 Effect of dilutive securities – stock options, restricted stock, and performance shares 400,971 Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock $ 55,972 31,922,638 $ 1.75 2015 Earnings (Numerator) Number of Shares (Denominator) Per Share Amount Basic EPS – Net earnings and weighted average common shares outstanding $ 59,722 31,158,142 $ 1.92 Effect of dilutive securities – stock options, restricted stock, and performance shares 477,496 Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock $ 59,722 31,635,638 $ 1.89 2014 Earnings (Numerator) Number of Shares (Denominator) Per Share Amount Basic EPS – Net earnings and weighted average common shares outstanding $ 52,826 30,381,310 $ 1.74 Effect of dilutive securities – stock options and restricted stock 790,412 Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock $ 52,826 31,171,722 $ 1.69 |
EMPLOYEE BENEFIT PLANS (Tables)
EMPLOYEE BENEFIT PLANS (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
EMPLOYEE BENEFIT PLANS [Abstract] | |
Change in benefit obligation | The actuarial recorded liabilities for such unfunded postretirement benefits are as follows: Change in benefit obligation: 2016 2015 Benefit obligation at beginning of year $ 958 $ 1,111 Initial adoption of new plan 444 - Service cost with interest to end of year 66 54 Interest cost 48 36 Participant contributions 5 5 Benefits paid (9 ) (6 ) Actuarial gain (101 ) (242 ) Benefit obligation at end of year $ 1,411 $ 958 |
Change in plan assets | Change in plan assets: 2016 2015 Fair value of plan assets at beginning of year $ - $ - Employer (reimbursement)/contributions 4 1 Participant contributions 5 5 Benefits paid (9 ) (6 ) Fair value of plan assets at end of year $ - $ - |
Amounts recognized in consolidated balance sheet | Amounts recognized in consolidated balance sheet: 2016 2015 Accumulated postretirement benefit obligation $ (1,411 ) $ (958 ) Fair value of plan assets - - Funded status (1,411 ) (958 ) Unrecognized prior service cost N/A N/A Unrecognized net (gain)/loss N/A N/A Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations) $ 1,411 $ 958 Accrued postretirement benefit cost (included in other long-term obligations) $ N/A $ N/A |
Components of net periodic benefit cost | Components of net periodic benefit cost: 2016 2015 2014 Service cost with interest to end of year $ 66 $ 54 $ 57 Interest cost 48 36 48 Amortization of prior service credit/(cost) 57 (18 ) (18 ) Amortization of (gain)/loss (10 ) - 6 Total net periodic benefit cost $ 161 $ 72 $ 93 |
Estimated future employer contributions and benefit payments | Estimated future employer contributions and benefit payments are as follows: Year 2017 $ 88 2018 106 2019 96 2012 90 2021 88 Years 2022-2026 581 |
Pension fund disclosure | Pension EIN/Pension Plan Pension Plan Protection Act FIP/RP Status Pending/ Contributions of Balchem Corporation Surcharge Imposed Expiration Date 2016 2015 2016 2015 2014 Central States, Southeast and Southwest Areas Pension Fund 36-6044243 Red as of 1/1/2016 Red as of 1/1/2015 Implemented $ 576 $ 515 $ 498 No 5/31/2017 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
COMMITMENTS AND CONTINGENCIES [Abstract] | |
Aggregate future minimum rental payments required under non-cancelable operating leases | Aggregate future minimum rental payments required under non-cancelable operating leases at December 31, 2016 are as follows: Year 2017 $ 2,436 2018 2,011 2019 1,702 2020 1,364 2021 1,245 Thereafter 8,752 Total minimum lease payments $ 17,510 |
ACCUMULATED OTHER COMPREHENSI41
ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
ACCUMULATED OTHER COMPREHENSIVE INCOME [Abstract] | |
Changes in accumulated other comprehensive income (loss) | The changes in accumulated other comprehensive income (loss) were as follows: 2016 Years Ended December 31, 2015 2014 Net foreign currency translation adjustment $ (1,390 ) $ (2,615 ) $ (2,972 ) Net change in postretirement benefit plan (see Note 10 for further information) Initial adoption of new plan (444 ) - - Net gain arising during the period 101 242 191 Amortization of prior service credit/(cost) 57 (18 ) (18 ) Amortization of (gain)/loss (10 ) - 6 Total before tax (296 ) 224 179 Tax (49 ) (72 ) (56 ) Net of tax (345 ) 152 123 Total other comprehensive income (loss) $ (1,735 ) $ (2,463 ) $ (2,849 ) Accumulated other comprehensive income/(loss) at December 31, 2016 consisted of the following: Foreign currency translation adjustment Postretirement benefit plan Total Balance December 31, 2015 $ (5,317 ) $ 203 $ (5,114 ) Other comprehensive (loss)/gain (1,390 ) (345 ) (1,735 ) Balance December 31, 2016 $ (6,707 ) $ (142 ) $ (6,849 ) |
SEGMENT INFORMATION (Tables)
SEGMENT INFORMATION (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
SEGMENT INFORMATION [Abstract] | |
Segment reporting information, by segment | Business Segment Net Sales: 2016 2015 2014 Human Nutrition & Health $ 297,134 $ 278,288 $ 206,101 Animal Nutrition & Health 161,119 165,763 176,477 Specialty Products 70,126 54,236 54,053 Industrial Products 24,825 54,205 104,752 Total $ 553,204 $ 552,492 $ 541,383 Business Segment Earnings Before Income Taxes: 2016 2015 2014 Human Nutrition & Health $ 38,156 $ 38,302 $ 21,260 Animal Nutrition & Health 28,686 27,851 23,687 Specialty Products 22,862 23,995 21,316 Industrial Products 1,949 5,594 16,532 Unallocated equity compensation - (1,462 ) - Transaction costs, integration costs and legal settlement (815 ) (324 ) (652 ) Interest and other income, net (7,904 ) (6,893 ) (5,091 ) Total $ 82,934 $ 87,063 $ 77,052 Depreciation/Amortization: 2016 2015 2014 Human Nutrition & Health $ 33,796 $ 30,537 $ 20,873 Animal Nutrition & Health 7,243 6,573 6,026 Specialty Products 3,787 1,225 1,385 Industrial Products 850 1,027 1,783 Total $ 45,676 $ 39,362 $ 30,067 Business Segment Assets: 2016 2015 2014 Human Nutrition & Health $ 709,337 $ 642,929 $ 656,130 Animal Nutrition & Health 121,860 107,459 90,650 Specialty Products 64,030 24,769 24,913 Industrial Products 10,477 16,191 32,330 Other Unallocated 42,922 88,338 57,508 Total $ 948,626 $ 879,686 $ 861,531 Other unallocated assets consist of certain cash, receivables, prepaid expenses, equipment and leasehold improvements, net of accumulated depreciation, and deferred income taxes, which the Company does not allocate to its individual business segments. Capital Expenditures: 2016 2015 2014 Human Nutrition & Health $ 14,470 $ 21,361 $ 3,475 Animal Nutrition & Health 6,577 17,854 7,383 Specialty Products 1,286 940 896 Industrial Products 701 1,145 1,445 Total $ 23,034 $ 41,300 $ 13,199 |
Geographic revenue information | Geographic Revenue Information: 2016 2015 2014 United States $ 420,821 $ 441,664 $ 420,324 Foreign Countries 132,383 110,828 121,059 Total $ 553,204 $ 552,492 $ 541,383 |
Geographic area data - long-lived assets (excluding intangible assets) | Geographic Area Data – Long-Lived Assets (excluding intangible assets): 2016 2015 2014 North America $ 154,007 $ 148,209 $ 121,090 Europe 11,747 10,306 10,498 Total $ 165,754 $ 158,515 $ 131,588 |
SUPPLEMENTAL CASH FLOW INFORM43
SUPPLEMENTAL CASH FLOW INFORMATION (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
SUPPLEMENTAL CASH FLOW INFORMATION [Abstract] | |
Supplemental cash flow information | Cash paid during the year for: 2016 2015 2014 Income taxes $ 30,741 $ 19,551 $ 25,304 Interest $ 6,669 $ 5,987 $ 4,685 Non-cash financing activities: 2016 2015 2014 Dividends payable $ 12,088 $ 10,727 $ 9,251 |
QUARTERLY FINANCIAL INFORMATI44
QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
QUARTERLY FINANCIAL INFORMATION (UNAUDITED) [Abstract] | |
Quarterly financial information | (In thousands, except per share data) 2016 2015 First Quarter Second Quarter Third Quarter Fourth Quarter First Quarter Second Quarter Third Quarter Fourth Quarter Net sales $ 135,141 $ 138,794 $ 138,509 $ 140,760 $ 144,862 $ 134,773 $ 140,128 $ 132,729 Gross profit 42,824 46,449 44,656 46,932 43,130 41,867 43,174 39,926 Earnings before income taxes 17,981 21,383 20,771 22,799 23,085 22,167 21,189 20,623 Net earnings 11,886 14,150 14,012 15,924 15,172 14,916 13,976 15,659 Basic net earnings per common share $ .38 $ .45 $ .44 $ .51 $ .49 $ .48 $ .45 $ .50 Diluted net earnings per common share $ .37 $ .44 $ .44 $ .50 $ .48 $ .47 $ .44 $ .49 |
BUSINESS DESCRIPTION AND SUMM45
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2016USD ($) | |
BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] | |
Change in carrying amount of goodwill as a result of changes to the fair value of assets acquired and liabilities assumed | $ 4,272 |
Goodwill [Roll Forward] | |
Goodwill, beginning of period | 383,906 |
Goodwill as a result of the Acquisition of Albion International, Inc. - see Note 2 | 55,905 |
Goodwill, end of period | 439,811 |
Human Nutrition and Health [Member] | |
Goodwill [Roll Forward] | |
Goodwill, beginning of period | 363,784 |
Goodwill, end of period | 404,187 |
Animal Nutrition and Health [Member] | |
Goodwill [Roll Forward] | |
Goodwill, beginning of period | 11,734 |
Goodwill, end of period | 11,734 |
Specialty Products [Member] | |
Goodwill [Roll Forward] | |
Goodwill, beginning of period | 7,160 |
Goodwill, end of period | 22,662 |
Industrial Products [Member] | |
Goodwill [Roll Forward] | |
Goodwill, beginning of period | 1,228 |
Goodwill, end of period | $ 1,228 |
Buildings [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives | 15 years |
Buildings [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives | 25 years |
Equipment [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives | 2 years |
Equipment [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Estimated useful lives | 28 years |
Customer Relationships and Lists [Member] | |
Acquired Finite-Lived Intangible Assets [Line Items] | |
Amortization Period | 10 years |
Trademarks & Trade Names [Member] | |
Acquired Finite-Lived Intangible Assets [Line Items] | |
Amortization Period | 17 years |
Developed Technology [Member] | |
Acquired Finite-Lived Intangible Assets [Line Items] | |
Amortization Period | 5 years |
Regulatory Registration Costs [Member] | Minimum [Member] | |
Acquired Finite-Lived Intangible Assets [Line Items] | |
Amortization Period | 5 years |
Regulatory Registration Costs [Member] | Maximum [Member] | |
Acquired Finite-Lived Intangible Assets [Line Items] | |
Amortization Period | 10 years |
Patents & Trade Secrets [Member] | Minimum [Member] | |
Acquired Finite-Lived Intangible Assets [Line Items] | |
Amortization Period | 15 years |
Patents & Trade Secrets [Member] | Maximum [Member] | |
Acquired Finite-Lived Intangible Assets [Line Items] | |
Amortization Period | 17 years |
Other [Member] | Minimum [Member] | |
Acquired Finite-Lived Intangible Assets [Line Items] | |
Amortization Period | 5 years |
Other [Member] | Maximum [Member] | |
Acquired Finite-Lived Intangible Assets [Line Items] | |
Amortization Period | 10 years |
ACQUISITION (Details)
ACQUISITION (Details) - USD ($) $ / shares in Units, $ in Thousands | Feb. 01, 2016 | Dec. 31, 2016 | Dec. 31, 2015 |
Estimated fair values of the assets acquired and liabilities assumed [Abstract] | |||
Goodwill | $ 439,811 | $ 383,906 | |
Unaudited pro forma information [Abstract] | |||
Albion's actual results included in the Company's consolidated income statement, net sales | 49,608 | 0 | |
Albion actual results included in the Company's consolidated income statement, net earnings | 2,938 | 0 | |
Supplemental pro forma combined financial information, net sales | 557,784 | 605,273 | |
Supplemental pro forma combined financial information, net earnings | $ 60,840 | $ 56,109 | |
Basic earnings per share (in dollars per share) | $ 1.93 | $ 1.80 | |
Diluted earnings per share (in dollars per share) | $ 1.91 | $ 1.77 | |
Specialty Products [Member] | |||
Estimated fair values of the assets acquired and liabilities assumed [Abstract] | |||
Goodwill | $ 22,662 | $ 7,160 | |
Albion International, Inc [Member] | |||
Business Acquisition [Line Items] | |||
Percentage owned of the "Acquisition" | 100.00% | ||
Amount paid to former shareholders | $ 110,600 | ||
Working capital acquired | $ 4,900 | ||
Term of expertise in leverages science | 60 years | ||
Tax deductible for income tax purposes | $ 2,020 | ||
Estimated fair values of the assets acquired and liabilities assumed [Abstract] | |||
Cash and cash equivalents | 4,949 | ||
Accounts receivable | 7,671 | ||
Inventories | 15,989 | ||
Property, plant and equipment | 7,217 | ||
Other assets | 1,200 | ||
Trade accounts payable | (1,104) | ||
Accrued expenses | (2,788) | ||
Bank debt | (884) | ||
Deferred income taxes | (13,990) | ||
Goodwill | 55,905 | ||
Amount paid to shareholders | 115,550 | ||
Albion bank debt paid on purchase date | 884 | ||
Total amount paid on acquisition date | 116,434 | ||
Unaudited pro forma information [Abstract] | |||
Acquisition-related costs | 26,210 | ||
Non-recurring expenses related to the fair value adjustments to acquisition-date inventory | 5,363 | ||
Albion International, Inc [Member] | Human Nutrition & Health [Member] | |||
Estimated fair values of the assets acquired and liabilities assumed [Abstract] | |||
Goodwill | 40,403 | ||
Albion International, Inc [Member] | Specialty Products [Member] | |||
Estimated fair values of the assets acquired and liabilities assumed [Abstract] | |||
Goodwill | 15,502 | ||
Albion International, Inc [Member] | Selling, General and Administrative Expenses [Member] | |||
Business Acquisition [Line Items] | |||
Transaction and integration related costs | $ 1,499 | ||
Albion International, Inc [Member] | Customer Relationships [Member] | |||
Estimated fair values of the assets acquired and liabilities assumed [Abstract] | |||
Intangible assets | 18,443 | ||
Useful life of intangible assets acquired | 10 years | ||
Albion International, Inc [Member] | Licensing Agreements [Member] | |||
Estimated fair values of the assets acquired and liabilities assumed [Abstract] | |||
Intangible assets | 6,658 | ||
Useful life of intangible assets acquired | 8 years | ||
Albion International, Inc [Member] | Trade Names [Member] | |||
Estimated fair values of the assets acquired and liabilities assumed [Abstract] | |||
Intangible assets | 7,224 | ||
Useful life of intangible assets acquired | 17 years | ||
Albion International, Inc [Member] | Developed Technology [Member] | |||
Estimated fair values of the assets acquired and liabilities assumed [Abstract] | |||
Intangible assets | $ 9,060 | ||
Useful life of intangible assets acquired | 5 years |
STOCKHOLDERS' EQUITY (Details)
STOCKHOLDERS' EQUITY (Details) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016USD ($)Plan$ / sharesshares | Dec. 31, 2015USD ($)$ / sharesshares | Dec. 31, 2014USD ($)$ / sharesshares | |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | |||
Impact of stock-based compensation cost on net earnings | $ | $ (4,473) | $ (4,395) | $ (2,926) |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Increase in cash flows from financing activities , excess tax benefits related to stock compensation | $ | $ 2,546 | $ 7,009 | $ 7,220 |
Number of share-based compensation plans | Plan | 1 | ||
Weighted Average Grant Date Fair Value [Abstract] | |||
Estimated share-based compensation expense for current fiscal year | $ | $ 6,900 | ||
Repurchase of common stock [Abstract] | |||
Number of shares authorized to be repurchased (in shares) | 3,763,038 | ||
Aggregate number of shares repurchased since inception (in shares) | 2,150,835 | ||
Number of shares remaining in treasury (in shares) | 0 | 1,089 | |
Number of shares acquired under the stock repurchase plan and subsequently reissued (in shares) | 24,912 | ||
Treasury stock acquired, average cost (in dollars per share) | $ / shares | $ 63.76 | ||
Stock options outstanding by price range [Abstract] | |||
Shares Outstanding (in shares) | 1,066,000 | ||
Weighted Average Remaining Contractual Term of Options Outstanding | 6 years 2 months 12 days | ||
Weighted Average Exercise Price of Options Outstanding (in dollars per share) | $ / shares | $ 45.32 | ||
Number of Options Exercisable (in shares) | 604,000 | ||
Weighted Average Exercise Price of Options Exercisable (in dollars per share) | $ / shares | $ 34.77 | ||
Stock Options [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares available for future awards (in shares) | 3,476,571 | ||
Weighted Average Assumptions [Abstract] | |||
Expected Volatility | 34.40% | 33.20% | 33.70% |
Expected Term | 5 years | 5 years 6 months | 5 years 7 months 6 days |
Risk-Free Interest Rate | 1.20% | 1.70% | 1.80% |
Dividend Yield | 0.50% | 0.60% | 0.50% |
Vesting period | 3 years | ||
Stock Option Activity [Abstract] | |||
Outstanding at beginning of year (in shares) | 1,017,000 | 1,470,000 | 1,893,000 |
Granted (in shares) | 341,000 | 209,000 | 313,000 |
Exercised (in shares) | (236,000) | (627,000) | (610,000) |
Forfeited (in shares) | (56,000) | (35,000) | (126,000) |
Outstanding at end of year (in shares) | 1,066,000 | 1,017,000 | 1,470,000 |
Exercisable at end of year (in shares) | 604,000 | 667,000 | 1,066,000 |
Weighted Average Exercise Price [Abstract] | |||
Outstanding at beginning of year (in dollars per share) | $ / shares | $ 37.29 | $ 27.35 | $ 20.94 |
Granted (in dollars per share) | $ / shares | 60.92 | 58.34 | 53.38 |
Exercised (in dollars per share) | $ / shares | 30.44 | 20.16 | 14.92 |
Forfeited (in dollars per share) | $ / shares | 58.23 | 52.97 | 56.03 |
Outstanding at end of year (in dollars per share) | $ / shares | 45.32 | 37.29 | 27.35 |
Exercisable at end of period (in dollars per share) | $ / shares | $ 34.77 | $ 29.19 | $ 21.52 |
Aggregate intrinsic value for outstanding stock options | $ | $ 41,161 | $ 23,927 | $ 57,742 |
Weighted average remaining contractual term for outstanding stock options | 6 years 2 months 12 days | ||
Aggregate intrinsic value for exercisable stock options outstanding | $ | $ 29,680 | ||
Weighted average remaining contractual term for exercisable stock options outstanding | 4 years 7 months 6 days | ||
Weighted-average fair value of options granted (in dollars per share) | $ / shares | $ 18.48 | $ 18.35 | $ 17.36 |
Total intrinsic value of stock options exercised | $ | $ 8,609 | $ 24,047 | $ 25,224 |
Restricted Stock [Member] | |||
Non-vested Restricted Stock [Roll Forward] | |||
Non-vested balance as of beginning of year (in shares) | 150,000 | 134,000 | 172,000 |
Granted (in shares) | 19,000 | 77,000 | 33,000 |
Vested (in shares) | (66,000) | (61,000) | (65,000) |
Forfeited (in shares) | (1,000) | 0 | (6,000) |
Non-vested balance as of end of year (in shares) | 102,000 | 150,000 | 134,000 |
Weighted Average Grant Date Fair Value [Abstract] | |||
Non-vested balance as of beginning of year (in dollars per share) | $ / shares | $ 47.46 | $ 38.13 | $ 33.69 |
Granted (in dollars per share) | $ / shares | 61.22 | 55.77 | 54.86 |
Vested (in dollars per share) | $ / shares | 40.96 | 37.35 | 34.19 |
Forfeited (in dollars per share) | $ / shares | 56.77 | 0 | 45.32 |
Non-vested balance as of end of year (in dollars per share) | $ / shares | $ 54.18 | $ 47.46 | $ 38.13 |
Unrecognized compensation cost related to non-vested shares | $ | $ 8,260 | $ 7,705 | $ 5,981 |
Weighted-average period of recognition for unrecognized compensation cost | 1 year 4 months 24 days | ||
Restricted Stock [Member] | Employee [Member] | |||
Weighted Average Assumptions [Abstract] | |||
Vesting period | 4 years | ||
Restricted Stock [Member] | Non-employee Director [Member] | |||
Weighted Average Assumptions [Abstract] | |||
Vesting period | 4 years | ||
Performance Shares [Member] | |||
Non-vested Restricted Stock [Roll Forward] | |||
Non-vested balance as of beginning of year (in shares) | 20,000 | 0 | 0 |
Granted (in shares) | 22,000 | 29,000 | 0 |
Vested (in shares) | 0 | 0 | 0 |
Forfeited (in shares) | (8,000) | (9,000) | 0 |
Non-vested balance as of end of year (in shares) | 34,000 | 20,000 | 0 |
Weighted Average Grant Date Fair Value [Abstract] | |||
Non-vested balance as of beginning of year (in dollars per share) | $ / shares | $ 58.77 | $ 0 | $ 0 |
Granted (in dollars per share) | $ / shares | 63.15 | 58.77 | 0 |
Vested (in dollars per share) | $ / shares | 0 | 0 | 0 |
Forfeited (in dollars per share) | $ / shares | 60.88 | 58.77 | 0 |
Non-vested balance as of end of year (in dollars per share) | $ / shares | $ 61.06 | $ 58.77 | $ 0 |
Performance Shares [Member] | Employee [Member] | |||
Weighted Average Assumptions [Abstract] | |||
Expected Volatility | 32.00% | 34.00% | |
Risk-Free Interest Rate | 0.88% | 1.00% | |
Dividend Yield | 0.60% | 0.50% | |
Vesting period | 3 years | ||
Weighted Average Grant Date Fair Value [Abstract] | |||
Initial TSR | (6.60%) | (6.90%) | |
Cliff vest | 100.00% | ||
1999 Stock Plan [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Initial number of common stock shares reserved for issuance (in shares) | 600,000 | ||
Increase in the number of shares of common stock reserved for issuance (in shares) | 600,000 | ||
1999 Stock Plan [Member] | Non-employee Director [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares purchased under restricted stock purchase agreements, minimum (in shares) | 500 | ||
Shares purchased under restricted stock purchase agreements, maximum (in shares) | 54,000 | ||
1999 Stock Plan [Member] | Stock Options [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Percentage of option grants exercisable after one year | 20.00% | ||
Percentage of option grants exercisable after two years | 60.00% | ||
Percentage of option grants exercisable after three years | 100.00% | ||
Expiration period of options granted | 10 years | ||
1999 Stock Plan [Member] | Restricted Stock [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares purchased under restricted stock purchase agreements, minimum (in shares) | 1,000 | ||
Shares purchased under restricted stock purchase agreements, maximum (in shares) | 20,250 | ||
Shares purchased under restricted stock purchase agreements, purchase price, minimum (in dollars per share) | $ / shares | $ 0.02 | ||
Shares purchased under restricted stock purchase agreements, purchase price, maximum (in dollars per share) | $ / shares | $ 0.07 | ||
Amended 1999 Stock Plan [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Initial number of common stock shares reserved for issuance (in shares) | 1,200,000 | ||
Second Amended 1999 Stock Plan [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Initial number of common stock shares reserved for issuance (in shares) | 6,000,000 | ||
ISO Plan [Member] | Stock Options [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expiration period of options granted | 10 years | ||
Non-Qualified Plan [Member] | Stock Options [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expiration period of options granted | 10 years | ||
Cost of Sales [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | |||
Stock-based compensation cost | $ | $ 1,040 | $ 854 | $ 593 |
Operating Expenses [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | |||
Stock-based compensation cost | $ | $ 5,984 | $ 5,975 | $ 3,964 |
$13.61 - $34.81 [Member] | |||
Stock options outstanding by price range [Abstract] | |||
Range of Exercise Prices, Minimum (in dollars per share) | $ / shares | $ 13.61 | ||
Range of Exercise Prices, Maximum (in dollars per share) | $ / shares | $ 34.81 | ||
Shares Outstanding (in shares) | 356,000 | ||
Weighted Average Remaining Contractual Term of Options Outstanding | 3 years 6 months | ||
Weighted Average Exercise Price of Options Outstanding (in dollars per share) | $ / shares | $ 25.40 | ||
Number of Options Exercisable (in shares) | 356,000 | ||
Weighted Average Exercise Price of Options Exercisable (in dollars per share) | $ / shares | $ 25.40 | ||
$38.10 - $59.95 [Member] | |||
Stock options outstanding by price range [Abstract] | |||
Range of Exercise Prices, Minimum (in dollars per share) | $ / shares | 38.10 | ||
Range of Exercise Prices, Maximum (in dollars per share) | $ / shares | $ 59.95 | ||
Shares Outstanding (in shares) | 406,000 | ||
Weighted Average Remaining Contractual Term of Options Outstanding | 6 years 7 months 6 days | ||
Weighted Average Exercise Price of Options Outstanding (in dollars per share) | $ / shares | $ 51.03 | ||
Number of Options Exercisable (in shares) | 224,000 | ||
Weighted Average Exercise Price of Options Exercisable (in dollars per share) | $ / shares | $ 46.89 | ||
$60.01 - $80.26 [Member] | |||
Stock options outstanding by price range [Abstract] | |||
Range of Exercise Prices, Minimum (in dollars per share) | $ / shares | 60.01 | ||
Range of Exercise Prices, Maximum (in dollars per share) | $ / shares | $ 80.26 | ||
Shares Outstanding (in shares) | 304,000 | ||
Weighted Average Remaining Contractual Term of Options Outstanding | 9 years | ||
Weighted Average Exercise Price of Options Outstanding (in dollars per share) | $ / shares | $ 61 | ||
Number of Options Exercisable (in shares) | 24,000 | ||
Weighted Average Exercise Price of Options Exercisable (in dollars per share) | $ / shares | $ 60.84 |
INVENTORIES (Details)
INVENTORIES (Details) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
INVENTORIES [Abstract] | ||
Raw materials | $ 20,751 | $ 16,786 |
Work in progress | 3,225 | 1,807 |
Finished goods | 33,269 | 27,492 |
Total inventories | 57,245 | 46,085 |
Reserve for inventory | $ 2,546 | $ 1,823 |
PROPERTY, PLANT AND EQUIPMENT49
PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | $ 245,141 | $ 229,505 | |
Less: Accumulated depreciation | 79,387 | 70,990 | |
Property, plant and equipment, net | 165,754 | 158,515 | |
Depreciation expense | 15,907 | 12,895 | $ 10,599 |
Land [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | 4,208 | 3,247 | |
Building [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | 45,735 | 33,051 | |
Equipment [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | 177,841 | 153,682 | |
Construction in Progress [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | $ 17,357 | $ 39,525 |
INTANGIBLE ASSETS (Details)
INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
INTANGIBLE ASSETS [Abstract] | |||
Goodwill | $ 439,811 | $ 383,906 | |
Identifiable intangible assets [Abstract] | |||
Gross Carrying Amount | 250,099 | 207,758 | |
Accumulated Amortization | 102,615 | 72,847 | |
Amortization of identifiable finite-lived intangible assets [Abstract] | |||
Amortization of identifiable intangible assets | 29,768 | 26,467 | $ 19,468 |
Finite-lived intangible assets, future amortization expense [Abstract] | |||
2,017 | 26,160 | ||
2,018 | 23,641 | ||
2,019 | 21,604 | ||
2,020 | 19,634 | ||
2,021 | 16,472 | ||
Indefinite-lived intangible assets | $ 0 | 0 | |
Customer Relationships and Lists [Member] | |||
Identifiable intangible assets [Abstract] | |||
Amortization Period | 10 years | ||
Gross Carrying Amount | $ 185,885 | 167,442 | |
Accumulated Amortization | $ 86,338 | 63,578 | |
Trademarks & Trade Names [Member] | |||
Identifiable intangible assets [Abstract] | |||
Amortization Period | 17 years | ||
Gross Carrying Amount | $ 39,241 | 32,014 | |
Accumulated Amortization | $ 9,260 | 5,704 | |
Developed Technology [Member] | |||
Identifiable intangible assets [Abstract] | |||
Amortization Period | 5 years | ||
Gross Carrying Amount | $ 12,260 | 3,200 | |
Accumulated Amortization | 3,358 | 1,057 | |
Other [Member] | |||
Identifiable intangible assets [Abstract] | |||
Gross Carrying Amount | 12,713 | 5,102 | |
Accumulated Amortization | $ 3,659 | $ 2,508 | |
Other [Member] | Minimum [Member] | |||
Identifiable intangible assets [Abstract] | |||
Amortization Period | 5 years | ||
Other [Member] | Maximum [Member] | |||
Identifiable intangible assets [Abstract] | |||
Amortization Period | 17 years |
EQUITY-METHOD INVESTMENT (Detai
EQUITY-METHOD INVESTMENT (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2016USD ($) | |
Schedule of Equity Method Investments [Line Items] | |
Percentage of production offtake | 66.66% |
Percentage of operating expenses to be absorbed | 66.66% |
St. Gabriel CC Company, LLC [Member] | |
Schedule of Equity Method Investments [Line Items] | |
Ownership percentage in joint venture | 66.66% |
Loss relating to joint venture's expenses | $ (293) |
Carrying value of joint venture | $ 4,553 |
St. Gabriel CC Company, LLC [Member] | Eastman Chemical Company [Member] | |
Schedule of Equity Method Investments [Line Items] | |
Ownership percentage in joint venture | 33.34% |
LONG TERM DEBT (Details)
LONG TERM DEBT (Details) - USD ($) $ in Thousands | Feb. 01, 2016 | Dec. 31, 2016 | Dec. 31, 2015 | May 07, 2014 |
Debt Instrument [Line Items] | ||||
Debt outstanding | $ 281,500 | |||
Term loan quarterly payment | $ 8,750 | |||
Maturity date | May 7, 2019 | |||
Term loan interest rate | 2.27% | |||
Undrawn revolving loan | $ 81,000 | |||
Maturities of Long-term Debt [Abstract] | ||||
Less current portion of long-term debt | 35,000 | $ 35,000 | ||
Total long-term debt | 226,490 | 260,963 | ||
Capitalized costs net of accumulated amortization | 1,010 | |||
Amortization expense pertaining to capitalized costs | 526 | $ 603 | ||
Term Loan [Member] | ||||
Debt Instrument [Line Items] | ||||
Amount of loan | $ 350,000 | |||
Maturities of Long-term Debt [Abstract] | ||||
2,017 | 35,000 | |||
2,018 | 35,000 | |||
2,019 | 192,500 | |||
Future principle payments | 262,500 | |||
Less unamortized debt financing costs | 1,010 | |||
Less current portion of long-term debt | 35,000 | |||
Total long-term debt | 226,490 | |||
Revolving Loan [Member] | ||||
Debt Instrument [Line Items] | ||||
Amount of loan | $ 100,000 | |||
Revolving loan used for funding of acquisition and general corporate purposes | $ 65,000 | |||
Maturities of Long-term Debt [Abstract] | ||||
2,017 | 0 | |||
2,018 | 0 | |||
2,019 | 19,000 | |||
Future principle payments | 19,000 | |||
Less unamortized debt financing costs | 0 | |||
Less current portion of long-term debt | 0 | |||
Total long-term debt | 19,000 | |||
Total Debt [Member] | ||||
Maturities of Long-term Debt [Abstract] | ||||
2,017 | 35,000 | |||
2,018 | 35,000 | |||
2,019 | 211,500 | |||
Future principle payments | 281,500 | |||
Less unamortized debt financing costs | 1,010 | |||
Less current portion of long-term debt | 35,000 | |||
Total long-term debt | $ 245,490 |
INCOME TAXES (Details)
INCOME TAXES (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Current [Abstract] | |||
Federal | $ 28,765 | $ 29,638 | $ 25,937 |
Foreign | 2,670 | 3,021 | 2,141 |
State | 2,483 | 2,982 | 2,412 |
Deferred [Abstract] | |||
Federal | (7,114) | (6,815) | (5,772) |
Foreign | 52 | 58 | 85 |
State | 106 | (1,543) | (577) |
Total income tax provision | $ 26,962 | 27,341 | 24,226 |
Federal statutory rate | 35.00% | ||
Income tax reconciliation [Abstract] | |||
Income tax at Federal statutory rate | $ 29,027 | 30,471 | 26,968 |
State income taxes, net of Federal income taxes | 1,510 | 556 | 1,182 |
Domestic production activities deduction | (3,299) | (2,709) | (2,567) |
Other | (276) | (977) | (1,357) |
Total income tax provision | 26,962 | 27,341 | 24,226 |
Deferred tax assets [Abstract] | |||
Inventories | 2,378 | 1,432 | |
Restricted stock and stock options | 5,100 | 4,956 | |
Other | 2,629 | 807 | |
Total deferred tax assets | 10,107 | 7,195 | |
Deferred tax liabilities [Abstract] | |||
Amortization | 56,111 | 49,726 | |
Depreciation | 27,435 | 22,464 | |
Prepaid expense | 0 | 658 | |
Other | 48 | 752 | |
Total deferred tax liabilities | 83,594 | 73,600 | |
Net deferred tax liability | 73,487 | 66,405 | |
Valuation allowance for deferred tax assets | 0 | 0 | |
Reconciliation of unrecognized tax benefits [Roll Forward] | |||
Balance at beginning of period | 6,570 | 5,205 | 3,076 |
Increases for tax positions of prior years | 332 | 943 | 1,922 |
Decreases for tax positions of prior years | (406) | (120) | (417) |
Increases for tax positions related to current year | 141 | 542 | 624 |
Balance at end of period | 6,637 | 6,570 | 5,205 |
Interest and penalties | 94 | 138 | $ 37 |
Accrued interest and penalties | $ 2,486 | $ 2,405 |
NET EARNINGS PER COMMON SHARE54
NET EARNINGS PER COMMON SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Earnings (Numerator) [Abstract] | |||||||||||
Basic EPS - Net earnings | $ 55,972 | $ 59,722 | $ 52,826 | ||||||||
Diluted EPS - Net earnings | $ 55,972 | $ 59,722 | $ 52,826 | ||||||||
Number of Shares (Denominator) [Abstract] | |||||||||||
Basic EPS - weighted average common shares outstanding (in shares) | 31,521,667 | 31,158,142 | 30,381,310 | ||||||||
Effect of dilutive securities - stock options, restricted stock, and performance shares (in shares) | 400,971 | 477,496 | 790,412 | ||||||||
Diluted EPS - weighted average common shares outstanding and effect of stock options and restricted stock (in shares) | 31,922,638 | 31,635,638 | 31,171,722 | ||||||||
Per Share Amount [Abstract] | |||||||||||
Basic EPS - Net earnings (in dollars per share) | $ 0.51 | $ 0.44 | $ 0.45 | $ 0.38 | $ 0.50 | $ 0.45 | $ 0.48 | $ 0.49 | $ 1.78 | $ 1.92 | $ 1.74 |
Diluted EPS - Net earnings (in dollars per share) | $ 0.50 | $ 0.44 | $ 0.44 | $ 0.37 | $ 0.49 | $ 0.44 | $ 0.47 | $ 0.48 | $ 1.75 | $ 1.89 | $ 1.69 |
Stock Options [Member] | |||||||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||||||||
Anti-dilutive stock options outstanding, excluded from diluted earnings per share calculation (in shares) | 2,500 | 194,372 | 56,500 |
EMPLOYEE BENEFIT PLANS (Details
EMPLOYEE BENEFIT PLANS (Details) $ in Thousands | 12 Months Ended | ||||
Dec. 31, 2016USD ($)Plan | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | |
EMPLOYEE BENEFIT PLANS [Abstract] | |||||
Number of savings plan | Plan | 2 | ||||
Provision for profit sharing contributions | $ 712 | $ 738 | $ 938 | ||
Provision for matching 401(k) savings plan contributions | 2,248 | 1,886 | 804 | ||
Change in benefit obligation [Roll Forward] | |||||
Benefit obligation at beginning of period | 958 | 1,111 | |||
Initial adoption of new plan | 444 | 0 | |||
Service cost with interest to end of year | 66 | 54 | 57 | ||
Interest cost | 48 | 36 | 48 | ||
Participant contributions | 5 | 5 | |||
Benefits paid | (9) | (6) | |||
Actuarial gain | (101) | (242) | |||
Benefit obligation at end of period | 1,411 | 958 | 1,111 | ||
Change in plan assets [Roll Forward] | |||||
Fair value of plan assets at beginning of year | 0 | 0 | |||
Employer (reimbursement)/contributions | 4 | 1 | |||
Participant contributions | 5 | 5 | |||
Benefits paid | (9) | (6) | |||
Fair value of plan assets at end of year | 0 | 0 | 0 | ||
Amounts recognized in consolidated balance sheet [Abstract] | |||||
Accumulated postretirement benefit obligation | $ (1,411) | $ (958) | |||
Fair value of plan assets | 0 | 0 | 0 | 0 | 0 |
Funded status | (1,411) | (958) | |||
Unrecognized prior service cost | |||||
Unrecognized net (gain)/loss | |||||
Net amount recognized in consolidated balance sheet (after ASC 715) (included in other long-term obligations) | 1,411 | 958 | |||
Accrued postretirement benefit cost (included in other long-term obligations) | |||||
Components of net periodic benefit cost [Abstract] | |||||
Service cost with interest to end of year | 66 | 54 | 57 | ||
Interest cost | 48 | 36 | 48 | ||
Amortization of prior service credit/(cost | 57 | (18) | (18) | ||
Amortization of (gain)/loss | (10) | 0 | 6 | ||
Total net periodic benefit cost | $ 161 | 72 | 93 | ||
Estimated future employer contributions and benefit payments [Abstract] | |||||
2,017 | 88 | ||||
2,018 | 106 | ||||
2,019 | 96 | ||||
2,020 | 90 | ||||
2,021 | 88 | ||||
Years 2022-2026 | $ 581 | ||||
Assumed health care cost trend rates [Abstract] | |||||
Trend rate assumed for next fiscal year | 7.07% | ||||
Ultimate health care cost trend rate | 4.50% | ||||
Year that rate reaches ultimate trend rate | 2,038 | ||||
Effect of one percentage point increase in health care cost trend rates on accumulated postretirement benefit obligation | $ 125 | ||||
Effect of one percentage point increase in health care cost trend rates on net periodic postretirement benefit cost | 15 | ||||
Effect of one percentage point decrease in health care cost trend rates on accumulated postretirement benefit obligation | 110 | ||||
Effect of one percentage point decrease in health care cost trend rates on net periodic postretirement benefit cost | $ 13 | ||||
Weighted average discount rate used in determining the accumulated postretirement benefit obligation | 3.40% | 3.70% | |||
Pension fund [Abstract] | |||||
Percentage that plans in the red zone are generally funded, maximum | 65.00% | ||||
Percentage that plans in the yellow zone are generally funded, maximum | 80.00% | ||||
Percentage that plans in the green zone are generally funded, minimum | 80.00% | ||||
Increase in contribution rate | 4.00% | ||||
Contributions to multiemployer pension fund as a percentage of total contributions to fund, maximum | 5.00% | ||||
Contributions of Balchem Corporation | $ 576 | $ 515 | $ 498 | ||
Surcharge Imposed | $ 0 | ||||
Expiration Date of collective-Bargaining Agreement | May 31, 2017 |
COMMITMENTS AND CONTINGENCIES56
COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands | 12 Months Ended | ||||||||||||
Dec. 31, 2016USD ($)ft²AreaSeller | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2013USD ($) | Dec. 31, 2012USD ($) | Dec. 31, 2011USD ($) | Dec. 31, 2010USD ($) | Dec. 31, 2009USD ($) | Dec. 31, 2008USD ($) | Dec. 31, 2007USD ($) | Dec. 31, 2006USD ($) | Dec. 31, 2005USD ($) | Dec. 31, 2004USD ($) | |
COMMITMENTS AND CONTINGENCIES [Abstract] | |||||||||||||
Operating lease term | 6 years | ||||||||||||
Office space subject to operating lease | ft² | 20,000 | ||||||||||||
Rent expense charged to operations | $ 3,134 | $ 2,414 | $ 1,595 | ||||||||||
Future minimum rental payments required under non-cancelable operating leases [Abstract] | |||||||||||||
2,017 | 2,436 | ||||||||||||
2,018 | 2,011 | ||||||||||||
2,019 | 1,702 | ||||||||||||
2,020 | 1,364 | ||||||||||||
2,021 | 1,245 | ||||||||||||
Thereafter | 8,752 | ||||||||||||
Total minimum lease payments | 17,510 | ||||||||||||
Slate Hill, New York Site [Member] | Maximum [Member] | |||||||||||||
Site Contingency [Line Items] | |||||||||||||
Annual monitoring costs | $ 5 | $ 5 | $ 5 | $ 5 | $ 5 | $ 5 | $ 5 | $ 5 | $ 5 | $ 5 | $ 5 | $ 5 | $ 5 |
Verona, Missouri Facility [Member] | Dioxin Contamination [Member] | |||||||||||||
Site Contingency [Line Items] | |||||||||||||
Number of areas of the site in which capping of areas of residual contamination was performed | Area | 4 | ||||||||||||
Monitoring period for groundwater and surface water prior to submission of risk assessment report | 2 years | ||||||||||||
Number of sellers who have the benefit of certain contractual indemnification by the prior owner | Seller | 1 |
FAIR VALUE OF FINANCIAL INSTR57
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($) $ in Thousands | Dec. 31, 2016 | Dec. 31, 2015 |
Money Market Funds [Member] | Level 1 [Member] | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Cash and cash equivalents | $ 776 | $ 773 |
ACCUMULATED OTHER COMPREHENSI58
ACCUMULATED OTHER COMPREHENSIVE INCOME, Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Changes in accumulated other comprehensive income (loss) [Abstract] | |||
Net foreign currency translation adjustment | $ (1,390) | $ (2,615) | $ (2,972) |
Net change in postretirement benefit plan (see Note 10 for further information) [Abstract] | |||
Initial adoption of new plan | (444) | 0 | 0 |
Net gain arising during the period | 101 | 242 | 191 |
Amortization of prior service credit/(cost) | 57 | (18) | (18) |
Amortization of (gain)/loss | (10) | 0 | 6 |
Total before tax | (296) | 224 | 179 |
Tax | (49) | (72) | (56) |
Net of tax | (345) | 152 | 123 |
Other comprehensive loss | $ (1,735) | $ (2,463) | $ (2,849) |
ACCUMULATED OTHER COMPREHENSI59
ACCUMULATED OTHER COMPREHENSIVE INCOME, Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Components of accumulated other comprehensive income/(loss) [Roll Forward] | |||
Balance | $ 463,705 | $ 391,898 | $ 331,358 |
Other comprehensive (loss)/gain | (1,735) | (2,463) | (2,849) |
Balance | 521,033 | 463,705 | 391,898 |
AOCI Attributable to Parent [Member] | |||
Components of accumulated other comprehensive income/(loss) [Roll Forward] | |||
Balance | (5,114) | (2,651) | 198 |
Balance | (6,849) | (5,114) | $ (2,651) |
Foreign Currency Translation Adjustment [Member] | |||
Components of accumulated other comprehensive income/(loss) [Roll Forward] | |||
Balance | (5,317) | ||
Other comprehensive (loss)/gain | (1,390) | ||
Balance | (6,707) | (5,317) | |
Postretirement Benefit Plan [Member] | |||
Components of accumulated other comprehensive income/(loss) [Roll Forward] | |||
Balance | 203 | ||
Other comprehensive (loss)/gain | (345) | ||
Balance | $ (142) | $ 203 |
SEGMENT INFORMATION (Details)
SEGMENT INFORMATION (Details) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2016USD ($) | Sep. 30, 2016USD ($) | Jun. 30, 2016USD ($) | Mar. 31, 2016USD ($) | Dec. 31, 2015USD ($) | Sep. 30, 2015USD ($) | Jun. 30, 2015USD ($) | Mar. 31, 2015USD ($) | Dec. 31, 2016USD ($)Facility | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | |
SEGMENT INFORMATION [Abstract] | |||||||||||
Number of filing facilities | Facility | 2 | ||||||||||
Percentage decrease of chlorides released in environment | 75.00% | ||||||||||
Segment information [Abstract] | |||||||||||
Net sales | $ 140,760 | $ 138,509 | $ 138,794 | $ 135,141 | $ 132,729 | $ 140,128 | $ 134,773 | $ 144,862 | $ 553,204 | $ 552,492 | $ 541,383 |
Earnings before income taxes | 22,799 | $ 20,771 | $ 21,383 | $ 17,981 | 20,623 | $ 21,189 | $ 22,167 | $ 23,085 | 82,934 | 87,063 | 77,052 |
Unallocated equity compensation | 0 | (1,462) | 0 | ||||||||
Transaction, integration costs, and legal settlement | (815) | (324) | (652) | ||||||||
Interest and other income, net | (7,904) | (6,893) | (5,091) | ||||||||
Depreciation/Amortization | 45,676 | 39,362 | 30,067 | ||||||||
Assets | 948,626 | 879,686 | 948,626 | 879,686 | 861,531 | ||||||
Capital expenditures | 23,034 | 41,300 | 13,199 | ||||||||
Human Nutrition & Health [Member] | Reportable Segments [Member] | |||||||||||
Segment information [Abstract] | |||||||||||
Net sales | 297,134 | 278,288 | 206,101 | ||||||||
Earnings before income taxes | 38,156 | 38,302 | 21,260 | ||||||||
Depreciation/Amortization | 33,796 | 30,537 | 20,873 | ||||||||
Assets | 709,337 | 642,929 | 709,337 | 642,929 | 656,130 | ||||||
Capital expenditures | 14,470 | 21,361 | 3,475 | ||||||||
Animal Nutrition and Health [Member] | Reportable Segments [Member] | |||||||||||
Segment information [Abstract] | |||||||||||
Net sales | 161,119 | 165,763 | 176,477 | ||||||||
Earnings before income taxes | 28,686 | 27,851 | 23,687 | ||||||||
Depreciation/Amortization | 7,243 | 6,573 | 6,026 | ||||||||
Assets | 121,860 | 107,459 | 121,860 | 107,459 | 90,650 | ||||||
Capital expenditures | 6,577 | 17,854 | 7,383 | ||||||||
Specialty Products [Member] | Reportable Segments [Member] | |||||||||||
Segment information [Abstract] | |||||||||||
Net sales | 70,126 | 54,236 | 54,053 | ||||||||
Earnings before income taxes | 22,862 | 23,995 | 21,316 | ||||||||
Depreciation/Amortization | 3,787 | 1,225 | 1,385 | ||||||||
Assets | 64,030 | 24,769 | 64,030 | 24,769 | 24,913 | ||||||
Capital expenditures | 1,286 | 940 | 896 | ||||||||
Industrial Products [Member] | Reportable Segments [Member] | |||||||||||
Segment information [Abstract] | |||||||||||
Net sales | 24,825 | 54,205 | 104,752 | ||||||||
Earnings before income taxes | 1,949 | 5,594 | 16,532 | ||||||||
Depreciation/Amortization | 850 | 1,027 | 1,783 | ||||||||
Assets | 10,477 | 16,191 | 10,477 | 16,191 | 32,330 | ||||||
Capital expenditures | 701 | 1,145 | 1,445 | ||||||||
Other Unallocated [Member] | |||||||||||
Segment information [Abstract] | |||||||||||
Assets | $ 42,922 | $ 88,338 | $ 42,922 | $ 88,338 | $ 57,508 |
SEGMENT INFORMATION, Geographic
SEGMENT INFORMATION, Geographic Revenue Information and Geographic Area Data - Long-Lived Assets (Excluding Intangible Assets) (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Revenues from External Customers and Long-Lived Assets [Line Items] | |||||||||||
Net sales | $ 140,760 | $ 138,509 | $ 138,794 | $ 135,141 | $ 132,729 | $ 140,128 | $ 134,773 | $ 144,862 | $ 553,204 | $ 552,492 | $ 541,383 |
Long-lived assets, excluding intangible assets [Abstract] | |||||||||||
Long-lived assets, excluding intangible assets | 165,754 | 158,515 | 165,754 | 158,515 | 131,588 | ||||||
United States [Member] | Reportable Geographical Components [Member] | |||||||||||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||||||||||
Net sales | 420,821 | 441,664 | 420,324 | ||||||||
Foreign Countries [Member] | Reportable Geographical Components [Member] | |||||||||||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||||||||||
Net sales | 132,383 | 110,828 | 121,059 | ||||||||
North America [Member] | Reportable Geographical Components [Member] | |||||||||||
Long-lived assets, excluding intangible assets [Abstract] | |||||||||||
Long-lived assets, excluding intangible assets | 154,007 | 148,209 | 154,007 | 148,209 | 121,090 | ||||||
Europe [Member] | Reportable Geographical Components [Member] | |||||||||||
Long-lived assets, excluding intangible assets [Abstract] | |||||||||||
Long-lived assets, excluding intangible assets | $ 11,747 | $ 10,306 | $ 11,747 | $ 10,306 | $ 10,498 |
SUPPLEMENTAL CASH FLOW INFORM62
SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Cash paid during the year for [Abstract] | |||
Income taxes | $ 30,741 | $ 19,551 | $ 25,304 |
Interest | 6,669 | 5,987 | 4,685 |
Non-cash financing activities [Abstract] | |||
Dividends payable | $ 12,088 | $ 10,727 | $ 9,251 |
QUARTERLY FINANCIAL INFORMATI63
QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
QUARTERLY FINANCIAL INFORMATION (UNAUDITED) [Abstract] | |||||||||||
Net sales | $ 140,760 | $ 138,509 | $ 138,794 | $ 135,141 | $ 132,729 | $ 140,128 | $ 134,773 | $ 144,862 | $ 553,204 | $ 552,492 | $ 541,383 |
Gross profit | 46,932 | 44,656 | 46,449 | 42,824 | 39,926 | 43,174 | 41,867 | 43,130 | 180,861 | 168,097 | 144,172 |
Earnings before income taxes | 22,799 | 20,771 | 21,383 | 17,981 | 20,623 | 21,189 | 22,167 | 23,085 | 82,934 | 87,063 | 77,052 |
Net earnings | $ 15,924 | $ 14,012 | $ 14,150 | $ 11,886 | $ 15,659 | $ 13,976 | $ 14,916 | $ 15,172 | $ 55,972 | $ 59,722 | $ 52,826 |
Basic net earnings per common share (in dollars per share) | $ 0.51 | $ 0.44 | $ 0.45 | $ 0.38 | $ 0.50 | $ 0.45 | $ 0.48 | $ 0.49 | $ 1.78 | $ 1.92 | $ 1.74 |
Diluted net earnings per common share (in dollars per share) | $ 0.50 | $ 0.44 | $ 0.44 | $ 0.37 | $ 0.49 | $ 0.44 | $ 0.47 | $ 0.48 | $ 1.75 | $ 1.89 | $ 1.69 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details) - St. Gabriel CC Company, LLC [Member] $ in Thousands | 12 Months Ended |
Dec. 31, 2016USD ($) | |
Related Party Transaction [Line Items] | |
Finished goods received from related party | $ 8,619 |
Receivable from related party | 9,317 |
Payable to related party | 8,619 |
Related party receivables recorded in other current assets | 515 |
Services Provided [Member] | |
Related Party Transaction [Line Items] | |
Revenues from related party | 1,837 |
Raw Materials Sold [Member] | |
Related Party Transaction [Line Items] | |
Revenues from related party | $ 7,480 |
Valuation and Qualifying Acco65
Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | ||
Allowance for Doubtful Accounts [Member] | ||||
Valuation and Qualifying Accounts Disclosure [Line Items] | ||||
Balance at beginning of year | $ 235 | $ 288 | $ 115 | |
Additions charged (credited) to costs and expenses | 417 | (1) | 238 | |
Deductions | [1] | (163) | (52) | (65) |
Balance at end of year | 489 | 235 | 288 | |
Inventory Reserve [Member] | ||||
Valuation and Qualifying Accounts Disclosure [Line Items] | ||||
Balance at beginning of year | 1,823 | 1,682 | 181 | |
Additions charged (credited) to costs and expenses | 905 | 369 | 2,073 | |
Deductions | [1] | (182) | (228) | (572) |
Balance at end of year | $ 2,546 | $ 1,823 | $ 1,682 | |
[1] | represents write-offs. |